Piramal Pharma Enhances Biologics Production Capacity to Address Growing Industry Requirements – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to cater to the growing demand for biologic therapies. The company has invested in upgrading its facilities and capabilities to enhance its biologics manufacturing services, including process development, scale-up, and commercial production.
The expansion is part of Piramal Pharma’s strategy to strengthen its position as a trusted partner for biopharmaceutical companies, providing end-to-end services for the development and manufacture of biologics. The company’s biologics business has been growing rapidly, driven by the increasing demand for biologic therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic disorders.
Piramal Pharma’s biologics manufacturing infrastructure is designed to meet the highest standards of quality, safety, and regulatory compliance. The company’s facilities are equipped with state-of-the-art equipment and technology, including single-use bioreactors, chromatography systems, and fill-finish lines. The company has also implemented advanced process control systems and quality management systems to ensure that its biologics products meet the required standards of quality and purity.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure includes the addition of new production lines, laboratories, and process development facilities. The company has also hired a team of experienced biologics manufacturing professionals, including process engineers, quality assurance specialists, and regulatory experts. This team will work closely with clients to develop and manufacture biologics products that meet their specific needs and requirements.
Piramal Pharma’s biologics manufacturing services include cell line development, process development, scale-up, and commercial production. The company also offers a range of analytical and testing services, including bioanalytical testing, immunogenicity testing, and stability testing. The company’s biologics products are designed to meet the needs of a range of therapeutic areas, including oncology, immunology, and rare diseases.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a significant impact on the biopharmaceutical industry, enabling the company to meet the growing demand for biologic therapies and providing biopharmaceutical companies with a trusted partner for the development and manufacture of biologics. With its enhanced capabilities and infrastructure, Piramal Pharma is well-positioned to play a key role in the development of new biologic therapies and the treatment of a range of diseases. Overall, the expansion is a significant step forward for Piramal Pharma and is expected to drive growth and innovation in the biopharmaceutical industry.
Fake versions of Sun Pharma’s cholesterol-lowering medications confiscated in Hyderabad
In a significant crackdown on counterfeit pharmaceuticals, the Telangana Drugs Control Administration (DCA) has seized fake versions of heart medications Rosuvas F 20 and Rosuvas F 10 in Hyderabad’s Koti area. The counterfeit cholesterol-lowering drugs, labeled under the name of Sun Pharmaceutical Industries Ltd, were discovered during intelligence-led raids on June 19, 2025. The DCA conducted surprise inspections at two distribution firms, Ganga Pharma Distributors and Sri Nandini Pharma, where they found fake versions of Rosuvas F 20 and Rosuvas F 10 with forged manufacturing dates and expiry dates.
Sun Pharmaceutical Industries Ltd has confirmed that these products were not manufactured by them, leaving no doubt that the drugs seized were counterfeit and illegal. The drugs, containing Rosuvastatin and Fenofibrate, are commonly prescribed to treat high cholesterol and triglyceride levels, and are crucial in preventing heart attacks, strokes, and angina. The DCA has warned that counterfeit drugs endanger patients’ lives, failing to treat the disease and leading to severe health complications.
The value of the seized counterfeit drugs is estimated at ₹3 lakh, and investigations are ongoing to trace the origin of the fake supply chain and bring the perpetrators to justice. This incident raises serious concerns about the integrity of the pharmaceutical distribution system, especially as India battles rising cases of lifestyle-related diseases, including heart ailments caused by processed food consumption and sedentary habits.
The proliferation of counterfeit heart medicines presents a dangerous new challenge to India’s already strained healthcare system. With lifestyle diseases on the rise, access to authentic and effective medication is more critical than ever. The DCA has vowed to intensify inspections, ensure supply chain vigilance, and protect public health from such deceptive and harmful practices. The agency’s efforts aim to prevent patients from unknowingly consuming fake medicines, which can lead to major cardiovascular events and negate the benefits of legitimate treatment.
The seizure of counterfeit drugs is a significant step towards ensuring public health safety, and the DCA’s commitment to protecting the pharmaceutical supply chain is crucial in preventing the spread of counterfeit medicines. The incident highlights the need for increased vigilance and action against counterfeit pharmaceuticals, which pose a significant threat to public health. By cracking down on counterfeit drugs, the DCA aims to safeguard the health and well-being of citizens, especially those suffering from lifestyle-related diseases.
Meet the woman, daughter of India’s wealthiest pharmaceutical mogul, who now helms a staggering Rs 3,950,000,000,000 company and is…
The article highlights the achievements of a woman who is the daughter of India’s richest pharmaceutical tycoon. She has taken the reins of her father’s company, which is valued at a staggering Rs 3,950,000,000,000 (approximately $52 billion USD). This makes her one of the most powerful businesswomen in India.
The woman, whose name is not mentioned in the article, has demonstrated exceptional leadership skills and has been instrumental in driving the company’s growth and success. Her father, the founder of the company, is reportedly proud of her accomplishments and has entrusted her with the responsibility of leading the business.
The company, which is a leading player in the pharmaceutical industry, has a diverse portfolio of products and services that cater to the needs of patients across the globe. Under her leadership, the company has expanded its operations, invested in research and development, and forged strategic partnerships with other companies to strengthen its position in the market.
The woman’s rise to the top is a testament to her hard work, dedication, and vision. She has overcome numerous challenges and has proven herself to be a capable and effective leader. Her success has also inspired many other women to pursue careers in business and leadership, and she is widely regarded as a role model for young entrepreneurs and professionals.
The article also highlights the company’s commitment to social responsibility and its efforts to make a positive impact on the community. The company has launched various initiatives to improve healthcare outcomes, support education and research, and promote sustainability. Under her leadership, the company has also strengthened its focus on innovation, digitalization, and customer-centricity.
Overall, the article showcases the achievements of a remarkable woman who has made a significant contribution to the pharmaceutical industry and the business world at large. Her story is an inspiration to many, and her leadership has paved the way for other women to take on leadership roles in their respective fields. With her at the helm, the company is poised for continued growth and success, and her legacy is sure to have a lasting impact on the industry and beyond.
Authorities in Hyderabad confiscate fake Sun Pharma cholesterol medication valued at Rs 3 lakhs
In a significant crackdown on counterfeit medicines, a large consignment of fake Sun Pharma cholesterol-lowering drugs worth approximately Rs 3 lakhs was seized in Hyderabad. The seizure is a result of a coordinated effort between law enforcement agencies and pharmaceutical regulatory bodies to combat the growing menace of counterfeit medicines in India.
The counterfeit drugs, which were designed to mimic the packaging and appearance of genuine Sun Pharma products, were intended to be sold in the market as legitimate medications. However, they were found to be of inferior quality and could have posed serious health risks to consumers if ingested.
The seizure highlights the gravity of the counterfeit medicines problem in India, which is estimated to be worth thousands of crores of rupees. Counterfeit medicines can cause harm to patients, damage the reputation of pharmaceutical companies, and undermine the trust of consumers in the healthcare system.
Sun Pharma, one of India’s largest pharmaceutical companies, has been a victim of counterfeiting in the past, with several instances of fake versions of its medicines being seized by authorities. The company has been working closely with law enforcement agencies and regulatory bodies to prevent the circulation of counterfeit medicines and protect its brand reputation.
The seizure of fake Sun Pharma cholesterol-lowering drugs in Hyderabad is a significant success for the authorities, who have been cracking down on counterfeit medicines in recent years. The government has implemented various measures to prevent counterfeiting, including the use of track-and-trace technology, serialization, and strict regulation of pharmaceutical manufacturing and distribution.
In addition to the seizure, the authorities are also investigating the source of the counterfeit medicines and the individuals involved in their manufacture and distribution. The perpetrators are likely to face severe penalties, including fines and imprisonment, for their role in producing and selling fake medicines.
Overall, the seizure of fake Sun Pharma cholesterol-lowering drugs in Hyderabad is a welcome step in the fight against counterfeit medicines in India. It highlights the need for continued vigilance and cooperation between law enforcement agencies, pharmaceutical companies, and regulatory bodies to prevent the circulation of fake medicines and protect the health and well-being of consumers. By working together, it is possible to reduce the incidence of counterfeiting and ensure that patients receive genuine, effective, and safe medicines.
Introducing Apollo’s Game-Changing Joint Preservation Program in India – A Breakthrough in Orthopedic Care
Apollo Hospitals has launched the Apollo Joint Preservation Program, a revolutionary initiative aimed at providing comprehensive, patient-centric joint care in India. The program focuses on early intervention, personalized treatment, and proactive approach to joint health, with the goal of preserving mobility and confidence. The program is designed to alleviate joint pain and potentially delay or avoid invasive procedures.
The program offers a range of innovative treatments, including platelet-rich plasma (PRP) therapy, ozone therapy, and orthobiologics, which empower patients to take control of their joint health. Patients will also receive comprehensive support services, including physiotherapy, rehabilitation, nutritional advice, and alternative therapies like yoga.
The program is tailored to the needs of patients suffering from joint pain, arthritis, inflammatory conditions, and ligament injuries. By emphasizing active and healthy lifestyle habits, the program aims to address discomfort and potentially prevent the need for surgical interventions.
Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, congratulated the team on the launch, stating that the program is designed to benefit individuals of all ages who may not be aware of treatment options for joint pain or degeneration. The program’s three key aspects are tailored advice, treatment (medical and surgical), and therapies (rehabilitation, nutrition, and alternative therapies).
Senior orthopaedic surgeons from Apollo Hospitals, including Dr. A. Navaladi Shankar, Dr. Kornad P. Kosygan, and Dr. Arun Kannan, also spoke at the launch, highlighting the program’s innovative therapies and comprehensive approach. They emphasized the importance of empowering patients to take control of their joint health and maintain an active lifestyle.
The program aims to provide a range of treatment options, including non-invasive treatments, which can potentially delay or avoid major joint health issues. Patients will have access to a wide array of comprehensive treatment options, including traditional and alternative therapies, to help them preserve their mobility and quality of life. With this initiative, Apollo Hospitals is committed to enhancing the quality of life for all, promoting a more active and fulfilling lifestyle.
Delhi High Court grants Natco permission to manufacture and market Roche’s life-changing spinal muscular atrophy treatment
In a landmark ruling, the Delhi High Court has refused to grant an injunction to Roche, a pharmaceutical company, in a patent dispute over a cancer drug called Evrysdi (Risdiplam). The Court’s decision was guided by precedent, citing a previous case where an injunction was denied in a cancer drug case due to high pricing and limited availability. According to the Court, the approved drug Evrysdi, which is used to treat Spinal Muscular Atrophy (SMA), is not available at reasonably affordable prices in India. Therefore, the Court opined that if another party can manufacture the drug and make it available at an affordable price, the public interest would outweigh the need for an injunction.
The Court further noted that SMA is a debilitating disease with no cure, and Evrysdi is the only approved drug for treatment in India. The Court’s decision to deny the injunction ensures wider access to treatment for patients with SMA, while allowing Roche to seek damages if it ultimately prevails in the case.
In effect, the Court is encouraging the development of affordable alternatives to Evrysdi, which would benefit patients with SMA. By doing so, the Court is promoting the public interest in access to healthcare, particularly for rare and debilitating diseases like SMA. The ruling is seen as a significant step towards making complex and expensive treatments more accessible to the masses, paving the way for greater innovation and competition in the pharmaceutical industry. Overall, the Delhi High Court’s decision is a significant victory for patients’ rights and has the potential to set a precedent for future patent disputes in the country.
Glenmark gets FDA nod for over-the-counter generic version of Pataday
Glenmark has received FDA clearance for its generic version of Alcon’s Pataday Once Daily Relief Ophthalmic Solution, olopatadine hydrochloride ophthalmic solution 0.2% over-the-counter (OTC). This generic medication will be distributed in the US by Glenmark Therapeutics, USA. The Pataday Once Daily Relief Ophthalmic Solution market had sales of approximately $50.7 million in the latest 52 weeks period ending February 22, 2025, according to Nielsen syndicated data. Marc Kikuchi, president and business head of North America at Glenmark, expressed his company’s excitement to expand its OTC ophthalmic portfolio, emphasizing its commitment to meeting market needs and providing high-quality OTC solutions for customers.
The approval of Glenmark’s olopatadine hydrochloride ophthalmic solution 0.2% OTC marks another significant milestone for the company, which has been actively expanding its presence in the OTC market. The company has a strong pipeline of products in various stages of development, with a focus on providing high-quality, affordable, and innovative solutions to patients. The availability of this generic medication will cater to the growing demand for affordable and effective eye care products, bringing relief to patients suffering from allergies, itchy, red, and watery eyes.
By offering a generic version of Pataday, Glenmark is expected to increasing access to this medication, making it more convenient and cost-effective for patients to manage their ophthalmic conditions. The company’s commitment to innovation, quality, and customer satisfaction has earned it a reputation as a reliable player in the pharmaceutical industry, further solidifying its position as a major player in the OTC market.
Biocon’s novel pharmaceutical blend, including norepinephrine and innovative therapies, achieves coveted USFDA clearance.
Biocon’s arm, Biocon Pharma, has received approval for its Norepinephrine Bitartrate Injection in the US, expanding its portfolio of complex injectables. The injection will be used to treat adults with acute hypotension and sodium nitroprusside/control of blood pressure. This approval is in addition to two other drug products that Biocon Pharma has received final US FDA approvals for: Lenalidomide Capsules and Dasatinib Tablets.
Lenalidomide Capsules are indicated for multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia of myelodysplastic syndromes (MDS) in adults. Dasatinib Tablets are approved to treat people aged 1 year and older with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Moreover, Biocon Pharma has received tentative approval for its abbreviated new drug application (ANDA) for Rivaroxaban Tablets USP, which will be supplied in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. Rivaroxaban is an oral anticoagulant used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the reduction of stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation.
These regulatory approvals mark a significant milestone for Biocon Pharma, demonstrating its commitment to offering affordable, high-quality complex generics to global markets. The company’s expansion into the US market with these products reinforces its presence in the pharma industry, providing patients with access to essential medicines at an affordable price.
Glenmark secures US FDA approval for Olopatadine Ophthalmic Solution
Glenmark Pharma has announced that its US subsidiary, Glenmark Therapeutics Inc., has received approval from the US Food and Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). This approval allows Glenmark to market the product in the US market, expanding its ophthalmic portfolio. The product is bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc.
This approval is significant, as the Pataday brand is a popular treatment for relieving itchy, red, and irritated eyes. The annual sales of the Pataday product in the US market reached approximately $50.7 million, according to Nielsen syndicated data for the 52 weeks ending February 2025. Glenmark’s President and Business Head of North America, Marc Kikuchi, expressed his excitement about expanding the company’s over-the-counter (OTC) ophthalmic portfolio, stating that it reaffirms Glenmark’s commitment to providing high-quality, OTC eye care solutions for consumers.
The approval of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) marks a significant milestone for Glenmark Therapeutics Inc. in the US market. With this product, Glenmark is well-positioned to capitalize on the growing demand for OTC eye care solutions, providing consumers with a reliable and effective treatment option for their eye care needs.
China’s Vice-Premier Meets with Industry Leaders from Apple, Pfizer, Cargill and More
Chinese Vice Premier He Lifeng recently met with the heads of several multinational corporations, including Apple, Pfizer, Cargill, MasterCard, and Eli Lilly, to reassure them of China’s potential for business growth and investment. The meetings were seen as a crucial step in maintaining a positive business environment and convincing foreign investors to continue expanding their presence in China.
At the meetings, Vice Premier He highlighted China’s economic strength, with the country’s GDP growth expected to continue to be driven by domestic consumption, investment, and exports. He emphasized the country’s commitment to further open up its economy to foreign investment and facilitate foreign companies’ participation in its development, while also promoting technological innovation and cooperation.
The Chinese government has taken a series of measures to improve the business environment, including streamlining regulations, reducing taxes, and increasing transparency. The government has also been working to boost the country’s infrastructure development, which is expected to drive economic growth and create more job opportunities.
The meeting with the heads of the multinational corporations was seen as a way for China to showcase its business environment and encourage foreign investment. The country has been actively courting foreign companies, particularly in the tech and healthcare sectors, to invest in its economy.
Apple, for instance, has been exploring new opportunities in China, including expanding its online retail presence and investing in artificial intelligence. Pfizer, meanwhile, has been partnering with Chinese companies to develop new treatments for diseases prevalent in China.
Cargill, a leading agricultural company, has been working with Chinese partners to develop the country’s agri-food industry, while MasterCard has been investing in digital payments and financial technology in China. Eli Lilly, a leading pharmaceutical company, has been expanding its presence in China’s pharmaceutical market.
The meetings with the heads of these companies are seen as a crucial step in maintaining a positive business environment and convincing foreign investors to continue expanding their presence in China. By showcasing the country’s economic strength and commitment to innovation, China is hoping to attract more foreign investment and continue to drive its economic growth.
Mankind Pharma clears hurdle as CDSCO panel approves bioequivalence study for Resmetirom Tablets.
Mankind Pharma, a leading pharmaceutical company in India, has reportedly received approval from the Central Drugs Standard Control Organization (CDSCO) panel for conducting a bioequivalence study of its Resmetirom Tablets. This development is significant for the company as it paves the way for the launch of a generic version of the branded drug in the Indian market.
The bioequivalence study is a critical step in the approval process for generic drugs, which involves comparing the pharmacokinetic and pharmacodynamic properties of the generic product with those of the branded product. The CDSCO panel’s approval indicates that Mankind Pharma’s Resmetirom Tablets have demonstrated comparable bioavailability, pharmacokinetics, and efficacy to the branded drug.
Resmetirom is a marketed branded product for the treatment of certain types of anemia, and its generic version is expected to provide an affordable alternative to patients. The Indian pharmaceutical market, one of the largest in the world, is often referred to as the “pharmacy of the world” due to its large population and significant demand for medicines.
The approval of the bioequivalence study is a testament to Mankind Pharma’s commitment to quality and research, as well as its ability to develop high-quality generic drugs that meet international standards. With this approval, the company can now proceed with the launch of its generic Resmetirom Tablets, which is expected to benefit patients who require this treatment.
The approval also demonstrates the CDSCO’s commitment to fostering a competitive and innovative pharmaceutical industry in India. The organization’s efforts to streamline the approval process and facilitate the development of generic drugs are expected to lead to increased access to affordable medicines for patients in India and other countries.
Overall, the approval of the bioequivalence study for Mankind Pharma’s Resmetirom Tablets is a significant development in the Indian pharmaceutical industry, marking a step towards making high-quality generic drugs more accessible to patients. With its commitment to research and development, Mankind Pharma is well-positioned to continue making a positive impact on the healthcare landscape in India and beyond.
Dr. [Name], former head of science at Pfizer, has joined the board of directors at Immunai.
Mikael Dolsten, a renowned pharmaceutical expert, has joined Immunai as a strategic advisor, bringing with him over 25 years of experience in leadership roles at major pharmaceutical companies, including Pfizer, Wyeth, Boehringer Ingelheim, and AstraZeneca. During his 15-year tenure at Pfizer, he led the development of 35 new drugs and vaccines, including the first COVID-19 vaccine, and oversaw research across various therapeutic areas. As a result, he contributed to the development of new treatments for diseases such as rheumatoid arthritis, stroke prevention, and cancer.
Dr. Dolsten’s expertise in leading drug development processes will be crucial in helping Immunai achieve its goal of integrating artificial intelligence (AI) into immunology and oncology. He believes that AI can significantly accelerate drug development by analyzing immune system activity at the single-cell level and enhance the success rates and efficiency of drug development.
Immunai’s AI model for the immune system is transforming how companies approach drug discovery and development. The company’s unique immune atlas, AMICA, and proprietary IDE engine provide valuable insights into drug mechanisms of action, treatment success rates, and biomarkers for treatment success. These insights can be used to determine drug dosage, identify patients who are most likely to respond to treatment, and predict treatment outcomes.
Dr. Dolsten’s appointment is a significant step in the growth of Immunai, which has already collaborated with AstraZeneca and Teva. The company, which has raised $270 million to date, is expanding its team and actively recruiting for data and AI positions. With Dr. Dolsten’s expertise leading the way, Immunai is poised to revolutionize drug development through its cutting-edge AI-driven approach.
Apollo Hospitals introduces its pioneering ‘Seniors First’ initiative in Karnataka, catering specifically to the healthcare needs of older citizens.
Apollo Hospitals, a leading healthcare provider, has launched a new program called “Seniors First” at its Bannerghatta hospital in Bengaluru, exclusively designed for senior citizens. The program aims to provide a comprehensive and seamless healthcare experience for seniors, breaking down traditional barriers in care delivery. The initiative brings together multidisciplinary teams, including doctors, nurses, physiotherapists, and social workers, to provide personalized health plans, continuous health monitoring, and rehabilitation support.
The program offers a range of services, including personalized wellness plans, proactive health monitoring, rehabilitation support, emotional and caregiver assistance, diet guidance, and 24×7 medical and homecare services. The hospital claims that the program is designed to provide a connected and compassionate healthcare ecosystem, focusing on the unique needs of seniors.
Karnataka Health Minister Dinesh Gundu Rao praised the initiative, stating that it is a vital step towards ensuring that the elderly receive healthcare that is not only advanced but also compassionate and accessible. The program is designed to cater to the needs of seniors, providing them with a range of services to improve their overall health and well-being.
By launching “Seniors First,” Apollo Hospitals is once again setting a new standard for healthcare in India, providing a benchmark for other healthcare providers to follow. The program is a testament to the hospital’s commitment to providing high-quality care to its patients, particularly the elderly, and its mission to create a healthier and more compassionate society.
Introducing ‘Seniors First’, a pioneering program at Apollo Hospital, specifically designed to cater to the needs of senior citizens.
Apollo Hospitals has launched a pioneering initiative called “Seniors First”, aimed at providing comprehensive healthcare services for senior citizens. This integrated geriatric care program focuses on preventive wellness, structured recovery after major medical procedures, and continuous health monitoring. The program brings together multi-specialist teams, hospital-to-home transitions, and personalized health plans to create a connected and compassionate care ecosystem for the elderly.
The initiative aims to bridge the existing gaps in geriatric care, offering support tailored to the specific health challenges faced by older adults. The program provides specialized services, including personalized wellness plans, proactive health monitoring, rehabilitation support, emotional and caregiver assistance, dietary guidance, and a dedicated helpline and concierge services.
The Health Minister, Dinesh Gundu Rao, inaugurated the initiative, emphasizing the importance of making advanced and accessible healthcare available to senior citizens. He noted that “This is a vital step in ensuring that our elderly receive not only the best medical care but also the dignity and support they deserve.”
According to Dr. Madhu Sasidhar, President and CEO of Apollo Hospitals, there is a pressing need for specialized geriatric care in India, where over 140 million senior citizens often struggle with multiple chronic conditions, frequent hospitalizations, and complex medication regimens. Seniors First is designed to address these challenges by offering a sustainable and personalized model of care.
Overall, Seniors First aims to provide a comprehensive and holistic approach to healthcare for senior citizens, focusing on their unique needs and ensuring they receive the support and dignity they deserve.
Fortis Escorts Okhla inaugurates dedicated adult vaccination clinic to promote proactive healthcare and shield individuals against prevalent diseases.
Fortis Escorts, Okhla, a leading healthcare provider, has launched a dedicated adult vaccination clinic to promote preventive healthcare and protect individuals from vaccine-preventable diseases. The clinic offers a range of adult vaccinations, including flu, pneumonia, and HPV vaccines, to adults aged 19 and above.
The clinic is staffed by experienced medical professionals and offers a convenient and confidential service for patients. The dedicated vaccination clinic aims to increase awareness about the importance of vaccinations and encourage adults to get vaccinated, thereby reducing the risk of illnesses and protecting themselves and others.
At the clinic, patients can receive a range of vaccinations, including:
* Influenza (flu) vaccine, which protects against seasonal flu
* Pneumococcal conjugate vaccine (PCV), which protects against severe forms of pneumococcal disease
* Human papillomavirus (HPV) vaccine, which protects against certain types of cancer and genital warts
* Other vaccines, such as the shingles vaccine and the Tdap vaccine, which protects against tetanus, diphtheria, and pertussis
The clinic also offers additional health services, including:
* Health check-ups and screenings
* Consultations with healthcare professionals
* Medication and treatment for minor illnesses
* Health education and counseling
By providing a dedicated adult vaccination clinic, Fortis Escorts, Okhla is taking a proactive approach to promoting preventive healthcare and protecting the community from vaccine-preventable diseases. The clinic is a convenient and accessible option for adults who want to take control of their health and wellbeing and reduce the risk of illnesses.
The clinic is open on a walk-in basis, and patients can make appointments in advance or attend the clinic without an appointment. The clinic is committed to providing a welcoming and confidential service, and patients can expect to receive personalized care and attention from experienced healthcare professionals.
Overall, the dedicated adult vaccination clinic at Fortis Escorts, Okhla is a valuable resource for individuals who want to take proactive steps to protect themselves and their loved ones from vaccine-preventable diseases. By offering a range of adult vaccinations and related health services, the clinic is promoting a culture of preventive healthcare and encouraging individuals to prioritize their health and wellbeing.
US Regulatory Agency Inspects Indian Drug Plant Connected to Fatalities in the US, Reveals Deficiencies
The US Food and Drug Administration (FDA) has finally visited a India-based generic drug manufacturing facility, Ranbaxy Laboratories, which was linked to several deaths in the United States due to contaminated generic blood thinner shots. The inspection was carried out in May 2014, almost a year after the FDA sent a warning letter to the company in June 2013.
The FDA’s visit to the factory in Gurgaon, India, uncovered significant problems, including poor manufacturing practices, inadequate quality control, and failure to comply with good manufacturing practices (GMPs). The FDA’s report highlighted numerous deficiencies, including:
1. Contamination: The FDA found evidence of contamination in the facility, including dust, debris, and chemicals, which could compromise the sterility of the products.
2. Inadequate sterility testing: The FDA found that the company was not performing adequate sterility testing on its products, including injectable products, which put patients at risk.
3. Inadequate cleaning and sanitizing: The FDA found that the company’s cleaning and sanitizing procedures were inadequate, which could lead to the introduction of contaminants into the products.
4. Failure to document records: The FDA found that the company’s records were incomplete and did not provide sufficient documentation of its manufacturing processes, quality control measures, and product testing.
5. Inadequate training: The FDA found that the company’s employees had not received adequate training on GMPs, which could lead to errors and contamination.
The FDA’s findings are significant, as an estimated 21,000 vials of contaminated Heparin, a blood thinner, were imported from India and sold in the US between 2001 and 2008, resulting in significant health problems and at least 81 reported cases of adverse reactions, including stroke, kidney failure, and even deaths.
The FDA’s inspection of Ranbaxy’s facility is a significant step towards ensuring that the company meets international standards of quality and safety. However, the findings highlight the need for greater oversight and regulation of foreign-based pharmaceutical manufacturers to prevent similar incidents in the future. The FDA has given the company 15 months to correct the deficiencies and pending the successful resolution of the issues, the agency may remove the import alert and allow the company to resume exporting products to the US.
Pfizer receives nod from CDSCO panel to conduct trials for showcasing cancer-fighting effects of its innovative drug, Disitamab Vedotin.
Pfizer has received a nod from the Central Drugs Standard Control Organization (CDSCO) panel to conduct a clinical trial of its anticancer drug, Disitamab vedotin, in India. The panel’s approval will enable the company to proceed with the study, which is expected to begin soon.
Disitamab vedotin is a cancer treatment that targets the HER2 protein, which is overexpressed in many aggressive forms of breast, gastric, and other types of cancer. The drug works by binding to the HER2 protein, which then triggers the destruction of the cancer cells.
The clinical trial will be conducted by Pfizer’s Indian subsidiary, Pfizer India, in collaboration with leading cancer hospitals and research institutions in the country. The trial will involve approximately 200 patients with advanced breast, stomach, and throat cancers, the company said.
CDSCO is the most important pharmaceutical regulator in India, responsible for ensuring the quality, safety, and efficacy of drugs available in the country.approval from the panel is an essential step in the regulatory process, allowing Pfizer to conduct clinical trials in India, which is seen as a cost-effective and efficient way to develop and test new drugs.
India is a significant market for pharmaceuticals, with a large patient base and a growing need for new and innovative treatments. Pfizer’s Disitamab vedotin has the potential to address this need, and the company is well-positioned to be a significant player in the Indian market.
In approving Pfizer’s proposal, the CDSCO panel cited the company’s submission of solid data on the drug’s efficacy and safety in preclinical studies, as well as its proposed plan for the conduct of the clinical trial, which includes measures to ensure patient safety and data integrity.
The success of the clinical trial will depend on a number of factors, including the effectiveness of Disitamab vedotin in treating various types of cancer, the potential for side effects, and the level of patient acceptance. If the drug is found to be effective and safe, it could provide a new treatment option for patients with advanced breast, stomach, and throat cancers in India and potentially other countries.
Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country’s first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the blood and slow digestion. Mounjaro is priced at ₹3,500 to ₹4,375 per month, depending on the dosage.
The company has faced competition from other foreign pharma companies, with plans to introduce similar products in the growing market. However, Mounjaro’s unique pricing strategy, which is expected to be around 14,000-17,500 per month, makes it an attractive option for Indian patients.
The demand for GLP-1 drugs, which help reduce weight, has boomed, with the market expected to reach $100 billion by 2030. However, rival semaglutide (Ozempic) goes off-patent in 2026, and generics makers like Cipla, Dr Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Biocon are gearing up to launch cheaper generic copies.
Despite this, experts expect Mounjaro to be a hit in India, given the high demand for weight loss drugs. According to a senior diabetologist, a significant percentage of his patients are overweight, and the use of Mounjaro could lead to a 15-20% pickup in patients with type-2 diabetes.
In addition, the growing number of people with obesity in India, from 180 million in 2021 to 450 million by 2050, could lead to increased demand for weight loss drugs like Mounjaro. The market for GLP-1 drugs for patients with diabetes in India has already doubled to $3.6 billion in 2024, driven by unauthorized use of drugs like Ozempic and Mounjaro through the grey market.
Pharmaceuticals giant Pfizer, energy utility Spire, and regional banking stalwart TriCo Bancshares have consistently generated strong yields, making them attractive dividend investments.
The article highlights three companies, Pfizer (PFE), Spire (SR), and TriCo Bancshares (TCBK), that have a long history of paying dividends and consistently increasing them, making them attractive to income-focused investors. Pfizer, for instance, has raised its dividend every year for the past 15 years, with a current yield of around 6.60%. Spire has increased its dividend consecutively for the last 22 years, with a current yield of 4.12%, while TriCo Bancshares has done so for the past 12 years, with a current yield of 3.22%.
The companies’ financial performance is also noted, with Pfizer’s quarterly revenue beating estimates in its most recent earnings report. Spire’s Q1 2025 earnings fell short of estimates, but TriCo Bancshares’ latest earnings report beat expectations. The article concludes that these companies are good choices for investors seeking reliable passive income, with their dividend yields and long history of consistent hikes making them attractive options.
Apollo meets the needs of 30% of its customers online, offering prompt delivery of its services.
Apollo 24|7, a healthcare company, has seen significant growth in its online business, with its 19-minute delivery service contributing to nearly 30% of daily orders. The service, which was first launched in Delhi and Noida in November 2023, has since expanded to six major cities and plans to scale to 20 cities by the end of 2025. The company expects its daily online order volume to rise to 60,000 by the end of the year, with the proportion of 19-minute deliveries remaining steady at 28-30%.
Apollo’s rapid delivery service is made possible through a combination of large-format stores and dark stores, with the company operating around 12-14 large stores and 10-12 dark stores. The service uses an in-house team for 19-minute deliveries, while other orders are fulfilled through logistics partners like Shadowfax.
Apollo’s CEO, Madhivanan Balakrishnan, believes that the company’s extensive product range and prescription validation model give it an edge in the market. The company requires customers to either upload a doctor’s prescription or schedule a verification call for prescription drugs, which helps to ensure that only valid prescriptions are fulfilled. This model is necessary for expanding beyond over-the-counter medications, and the company is prepared to adapt to the growing competition in the market.
While there may be challenges in implementing this model, Balakrishnan notes that the 19-minute delivery service has not posed a significant challenge for the company so far. With its continued focus on innovation and customer satisfaction, Apollo 24|7 is well-positioned to maintain its position in the market.
Lupin earns Silver Medal for EcoVadis’ sustainability excellence awards
Lupin, a global pharmaceutical company, has been awarded the EcoVadis Silver Medal for sustainability excellence. The award recognizes Lupin’s commitment to sustainability across its entire value chain, from sourcing and production to distribution and end-of-life environmental management.
EcoVadis is a leading platform for sustainability ratings and performance improvement, providing a comprehensive assessment of companies’ environmental, social, and governance (ESG) performance. The Silver Medal is the second-highest award offered by EcoVadis, indicating that Lupin has demonstrated a strong track record of sustainability performance over the past year.
Lupin’s sustainability efforts focus on six key areas: environment, social, governance (ESG), value chain engagement, community development, and stakeholder engagement. The company has made significant progress in reducing its environmental impact, including a 25% reduction in energy consumption and a 30% decrease in greenhouse gas emissions since 2015.
In addition, Lupin has implemented various social initiatives, such as employee engagement programs, diversity and inclusion initiatives, and community development projects. The company has also strengthened its governance structure, ensuring transparency and accountability in its decision-making processes.
The award is a testament to Lupin’s commitment to sustainability and its efforts to create a positive impact on the environment, society, and its stakeholders. The company plans to continue its sustainability journey, exploring new opportunities for growth while minimizing its environmental footprint and promoting positive social change.
The EcoVadis Silver Medal is a milestone achievement for Lupin, demonstrating its leadership in the pharmaceutical industry. The award also reinforces the company’s commitment to transparency, accountability, and continuous improvement. With this recognition, Lupin aims to inspire other organizations to follow its lead in embracing sustainability as a key business strategy.
Biotechnology company Biocon is facing a patent infringement lawsuit from Impax over its generic version of Rytary, a US-approved medication.
Biocon, an Indian generic drug manufacturer, has been hit with a patent infringement complaint in the US District of New Jersey by Impax Laboratories. The complaint is related to Biocon’s Abbreviated New Drug Application (ANDA) to sell a generic version of the Parkinson’s drug Rytary. The patents-in-suit include US Patent Nos. 8,557,283, 9,089,608, 9,463,246, 9,533,046, and 9,901,640, as well as other Rytary patents listed in the FDA’s Orange Book.
This development comes as a significant challenge for Biocon, which is already facing intense competition in the generic drug market. The company is known for its innovative approaches to drug making, including the use of biotechnology and biosimilars. However, this complaint may force Biocon to re-evaluate its strategy and potentially delay the launch of its generic version of Rytary.
The patents-in-suit are a key part of Impax’s intellectual property portfolio, and the lawsuit could have significant implications for the generic drug industry. The dispute highlights the need for companies to carefully navigate the complex web of patents and intellectual property rights when developing and marketing new medicines.
The outcome of this lawsuit could have far-reaching implications for Biocon and the broader generic drug industry. As the world’s leading source of regulatory change, MLex provides real-time updates and analysis on the latest developments in the pharmaceutical industry. With our expertise, you’ll be better equipped to anticipate and respond to changes in the regulatory landscape, ensuring your business remains ahead of the curve.
Piramal Pharma receives regulatory approval to market Neoatricon in the UK, paving the way for its availability in the market.
Piramal Pharma Limited, in collaboration with BrePco Biopharma Ltd, has received regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Naeoatricon, a new pediatric-strength dopamine hydrochloride infusion for the treatment of hypotension in neonates, infants, and children. Piramal Critical Care (PCC) has secured commercialization rights for the EU, UK, and Norway, and will manage the product in these regions.
Naeoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of dopamine hydrochloride, available in two concentrations: 1.5mg/mL in a 30 mL vial and 4.5mg/mL in a 50 mL vial. Until now, there has been no approved dopamine hydrochloride formulation specifically indicated for use in neonates, infants, or children, with off-label use being a common practice.
The approval of Naeoatricon aims to address this gap, ensuring accurate dosing, minimizing the risk of under or overdosing, and reducing preparation time in neonatal and pediatric intensive care units (NICU & PICU), thus enabling faster intervention in emergency settings. With this approval, Naeoatricon sets a new standard in pediatric critical care.
The availability of Naeoatricon is a significant development in the field of pediatrics, as it provides a safe and reliable solution for healthcare professionals and parents. It aims to improve patient outcomes and optimize treatment in neonatal and pediatric critical care units, ultimately leading to better health outcomes for the most vulnerable patients.
Meet the scion of Hyderabad’s wealthiest businessman, at the helm of a gargantuan Rs 1.55 lakh crore corporation…
Dr. Kiran S Divi is the Director and CEO of Divi’s Laboratories Ltd, a leading manufacturer of generic drugs, since January 2020. Prior to his current role, he gained extensive knowledge and understanding of the pharmaceutical industry, with a focus on the US generic market. He is the son of Dr. Murali K Divi, the founder of the company and one of the richest pharma billionaires in the country with a net worth of USD 9.5 billion.
Dr. Kiran Divi holds a bachelor’s degree in Pharmacy from Mangalore University, a post-graduate degree in Pharmacy from Jawaharlal Nehru Technological University, and a PhD degree from Gandhi Institute of Technology and Management, Visakhapatnam. He has been with Divi’s Laboratories since August 2001 and has played a crucial role in developing high-quality business strategies and plans that align with the company’s short-term and long-term objectives.
As CEO, Dr. Kiran Divi oversees all corporate functions and operations at the manufacturing facilities. He is joined by his sister, Nilima Prasad Divi, who has been the company’s whole-time Director (commercial) since July 2012. Together, the siblings and their father, Dr. Murali K Divi, work together to run the company, which has a market cap of over Rs 1.55 lakh crore as of March 19. Under Dr. Kiran’s leadership, the company has achieved significant milestones and is well-positioned for continued growth and success in the pharmaceutical industry.
Sun Pharma Establishes Headquarters in New Jersey with Innovative ‘Emerge’ Program
The New Jersey Economic Development Authority (NJEDA) has approved several initiatives to support the state’s economic growth, including tax credits for Sun Pharmaceutical Industries Inc.’s plan to open a new U.S. headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. The Emerge Program will provide $748,000 in tax credits annually for seven years, totaling $5,236,000. Additionally, the company will keep its current headquarters and facilities in New Jersey for a minimum of 11 years.
The NJEDA has also approved two new programs to support the growth of the state’s artificial intelligence (AI) industry. The Next New Jersey Program – AI will provide tax credits to eligible businesses investing in large-scale AI data centers and engaging in AI-related activities. The AI Innovation Challenge Administration Grant Program will provide $3.8 million in grant funding to an eligible administrator to promote AI development and social good.
Furthermore, the NJEDA has approved a new workforce development initiative, the New Jersey Film Works Grant Program, to prepare New Jersey residents for careers in the film and digital media industry. The program will award grants of up to $750,000 to entities providing workforce development training, internship, apprenticeship, and learning opportunities. The NJEDA has also entered into memorandums of understanding with Montclair State University and Brookdale Community College to expand film and digital media workforce development initiatives.
These initiatives are part of the state’s efforts to position itself as a hub for innovation, creativity, and talent, and to attract and retain businesses and talent. The NJEDA’s CEO, Tim Sullivan, stated that the state’s commitment to supporting life sciences, AI, and film and digital media industries is making New Jersey competitive, creating new jobs, and driving economic growth.
In-Depth Market Research Report on Urinary Tract Infection Treatment 2025-2033, Including Key Market Analysis and Competitive Insights from Leading Players Like AstraZeneca, Bayer, GSK, Johnson & Johnson, Novartis, Pfizer, Merck, Dr Reddy’s, and BMS
The Urinary Tract Infection (UTI) market is expected to reach a market size of USD 11.64 billion by 2033, growing at a CAGR of 2.74% from 2025 to 2033. The primary drivers of the market are the increasing incidence of UTIs, growing awareness of the importance of prompt detection, and advancements in healthcare infrastructure. The increasing prevalence of UTIs in women, the elderly, and people with long-term illnesses such as diabetes is also contributing to the market growth.
The report identifies the following key trends and drivers:
* Increasing awareness of UTI symptoms and the importance of early detection, which is leading to a rise in diagnostic procedures and therapies.
* Advancements in diagnostic techniques and treatments, such as non-antibiotic medications like probiotics and herbal remedies.
* Growing demand for preventive measures and education on UTI prevention and management.
* Increasing use of digital platforms and public health campaigns to raise awareness about UTIs.
On the other hand, the report highlights the following challenges in the market:
* Antibiotic resistance, which is hampering the treatment of UTIs and requiring the development of new treatments and diagnostic techniques.
* High recurrence rates of UTIs, which are leading to increased healthcare expenses and a higher risk of complications.
The report also provides an overview of the key companies operating in the market, including AstraZeneca, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer, Merck & Co. Inc., and Dr. Reddy’s Laboratories Ltd.
Overall, the report provides a comprehensive analysis of the UTI market, highlighting the key trends, drivers, and challenges, as well as providing insights into the competitive landscape and key companies operating in the market.
Rendering Medical Care to Bengalureans Amidst the COVID-19 Pandemic – Apollo Hospitals
Summary:
The article discusses the implementation of Duk Game da Bambancin (DGB) by Apollo Hospitals in the wake of the COVID-19 pandemic. DGB is an innovative platform that utilizes digital technology to connect people with the healthcare system, ensuring efficient and effective management of patients and resources. Introduced by Apollo Hospitals, a leading healthcare provider in India, DGB has been instrumental in ensuring continuity of care during the pandemic.
Key features of DGB include:
- Remote consultations: Patients can now consult with healthcare professionals remotely, reducing the need for in-person visits to hospitals. This has helped to reduce crowding and transmission risks.
- Telemedicine services: Apollo Hospitals has leveraged digital communication platforms to enable online consultations, medication management, and case monitoring. This has improved access to healthcare services, particularly for those in remote areas or with mobility issues.
- Digital health records: DGB ensures seamless tracking and management of patient records, enabling healthcare professionals to access vital information quickly and securely.
- Real-time monitoring: Apollo Hospitals’ team can now monitor patient conditions in real-time, enabling early detection and response to potential complications.
- Streamlined operations: DGB has enabled hospitals to optimize patient flow, reduce waiting times, and minimize the use of physical resources, thereby reducing costs.
The implementation of DGB by Apollo Hospitals has several benefits:
- Enhanced patient experience: Patients can now access healthcare services from the comfort of their own homes, reducing anxiety and stress associated with hospital visits.
- Improved care coordination: Healthcare professionals can now collaborate more effectively, ensuring continuity of care and reducing gaps in treatment.
- Reduced healthcare expenditure: By reducing the need for in-person visits and streamlining operations, Apollo Hospitals can allocate resources more efficiently, leading to cost savings.
- Increased access to care: DGB has enabled Apollo Hospitals to reach a broader patient base, particularly those in rural areas or with mobility issues, improving access to healthcare services.
In conclusion, the implementation of Duk Game da Bambancin (DGB) by Apollo Hospitals has revolutionized the way healthcare is delivered during the COVID-19 pandemic. The innovative platform has enabled remote consultations, telemedicine services, and real-time monitoring, improving patient experience, care coordination, and resource allocation. As the world continues to navigate the pandemic, DGB serves as a model for other healthcare providers to follow, ensuring continuity of care and improving healthcare outcomes.
Piramal Pharma sets its sights on ambitious $2 billion revenue target by FY30, poised for a decade of exponential growth.
Piramal Pharma, a multi-faceted pharmaceutical company, is poised to achieve its goal of reaching $2 billion in revenues and becoming one of the top 10 companies in its addressable markets by 2030, according to Chairperson Nandini Piramal. The company has been growing at a rate of 10-15% across its various business verticals over the past few years. In the last nine months of FY25, Piramal Pharma reported a growth of 14% compared to the same period in FY24, with revenues of ₹6,397 crore.
One of the company’s main growth drivers is its contract development and manufacturing (CDMO) business, which accounted for 58% of its revenues in FY24. The CDMO business has seen an 18% growth in the last three quarters and aims to grow to $1.2 billion with an EBITDA margin of 25% by 2030. The company’s CDMO business focuses on differentiated services and on-patent molecules, with a strong pipeline of over 150 projects across multiple phases, including 34% in Phase 3 clinical trials. Piramal expects at least half of these products to become commercial and offer long-term manufacturing opportunities for large pharma and emerging biotechs.
The company’s other business verticals, including complex hospital generics, India consumer healthcare, and a joint venture with Abbvie for ophthalmic products, are also performing well. With its global presence and diversified portfolio, Piramal Pharma is well-positioned to achieve its ambitious goals and solidify its position in the pharmaceutical industry.
Lupin gains provisional clearance from the US FDA for its Amifampridine Tablets
Lupin Limited, a pharmaceutical company, has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application for Amifampridine Tablets, 10mg. This product is indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older. The drug is a generic version of Firdapse Tablets, 10mg, which has an estimated global net sale of $306 million for the fiscal year ended December 31, 2024.
The product will be manufactured at Lupin’s Goa facility in India, making it a significant milestone for the company. The tentative approval is a crucial step towards making the drug available to patients at an affordable price, as it allows the company to market and sell the product in the US market. The drug is expected to be a major contributor to the company’s revenue, given its high estimated global net sales.
Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder that affects the nervous system and can cause muscle weakness and paralysis. The condition can significantly impact daily life, making it essential to have effective treatment options available. With this approval, Lupin’s Amifampridine Tablets, 10mg, is set to provide a cost-effective alternative to existing treatment options, thereby improving patient access to the medication.
The approval is a testament to Lupin’s commitment to providing high-quality and affordable generic medicines to patients worldwide. The company’s Goa facility has a reputation for producing high-quality products, and this approval is a reflection of the facility’s capabilities. Overall, this approval is a significant achievement for Lupin, and the company is expected to benefit significantly from the sale of this product in the US market.
Zydus Lifesciences secures FDA approval in the US for its 60mg Apalutamide Tablets
Zydus Lifesciences has obtained final approval from the US Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, also known as Erleada Tablets, 60 mg. The drug is an androgen receptor inhibitor, primarily used to treat patients with metastatic castration-sensitive prostate cancer. With this approval, Zydus Lifesciences Ltd, located in Ahmedabad, will produce the medicine.
According to IQVIA, Apalutamide tablets generated $1.099 billion in annual sales in the United States as of January 2025. This significant revenue milestone highlights the importance of this medication in the market. The drug has been increasingly in demand in recent years due to its ability to slow or stop the growth of prostate cancer cells.
The approval is a significant achievement for Zydus Lifesciences, demonstrating the company’s capabilities in manufacturing complex pharmaceutical products. With this approval, Zydus Lifesciences will be able to cater to the growing demand for Apalutamide tablets in the United States and other markets where it is approved for use. The company’s ability to produce this critical medication will ensure a steady supply chain and availability of the drug for patients who rely on it for treatment.
The production of Apalutamide tablets at Zydus Lifesciences Ltd’s facility in Ahmedabad will further strengthen the company’s position as a key player in the global pharmaceutical market. The facility’s state-of-the-art infrastructure and experienced team will ensure the highest quality and compliance with international standards, guaranteeing the production of high-quality medicine that meets the required regulations and standards.
In summary, the approval by the USFDA to manufacture Apalutamide Tablets 60 mg (Erleada Tablets, 60 mg) is a significant milestone for Zydus Lifesciences, as it expands the company’s product portfolio and increases its global presence in the pharmaceutical industry. The production of this critical medication will also ensure a steady supply of the drug for patients who rely on it for treatment, thereby making a positive impact on public health.
Johor is set to become Asia’s largest insulin hub, thanks to a RM1.1 billion investment boost from Biocon, as reported in the New Straits Times.
Johor has emerged as a prime location to become Asia’s largest insulin hub, with Indian biotech major Biocon’s RM1.1 billion (approximately US$274 million) investment to establish a manufacturing facility in the state.
Biocon, one of India’s largest biotechnology company, announced plans to invest in a new facility in Johor, which will produce insulin and other biotechnology products. The investment is expected to create over 1,000 high-skilled jobs during the construction phase and around 500 permanent positions after the facility is operational.
The new facility, expected to be operational by 2025, will be built on a 20-acre site in Johor’s Nusajaya region. It will feature cutting-edge production technology, including advanced fermentation facilities and isolators, to produce insulin and other essential biotechnology products. The facility will be designed to meet global regulatory standards and produce high-quality products.
Biocon’s investment in Johor is a significant boost to the state’s biotechnology sector, which has been growing rapidly in recent years. The company has chosen Johor for its strategic location, business-friendly environment, and easy access to the Southern Corridor’s BioXploit, a biotech park and an eco-system of biotech companies, research institutions, and academic centers.
The investment is expected to contribute to the development of Johor’s biotechnology industry, which has seen significant growth in recent years, driven by the state government’s efforts to promote the sector. The state has set a target to make Biotechnology a vital contributor to the state’s economy by 2025, with a projected growth rate of 10% per annum.
The investment will also provide a significant boost to the local economy, generating additional revenue and creating new job opportunities. The facility will also contribute to the state’s human capital development by providing training and skills development programs to locals, enabling them to participate in the growing biotechnology industry.
In conclusion, Johor’s emergence as Asia’s largest insulin hub will be a significant milestone in the region’s biotechnology industry. With Biocon’s RM1.1 billion investment, the state is poised to become the production hub for insulin and other biotechnology products, creating a vast array of job opportunities and contributing to the state’s economic growth. The investment is set to further solidify Johor’s position as a key player in the global biotechnology landscape.
Apollo Hospitals deepens its commitment to AI-driven innovation, injecting additional investment to revolutionize hospital operations.
Apollo Hospitals, a leading healthcare provider in India, is increasing its investment in artificial intelligence (AI) to improve operational efficiency and reduce administrative tasks for healthcare professionals. The hospital chain, which operates over 10,000 beds, has been allocating 3.5% of its digital budget to AI in the past two years and plans to increase this investment to free up more time for doctors and nurses.
Apollo’s goal is to use AI to automate tasks such as medical documentation, diagnostic support, and patient records management, allowing healthcare professionals to focus on more critical tasks. The hospital is developing AI-powered tools to analyze electronic medical records, provide diagnostic recommendations, and assist with test ordering and treatment plans. Additionally, Apollo is working on an AI-powered system to help clinicians select appropriate antibiotics.
The company plans to expand its bed capacity by one-third in the next four years, with a portion of the revenue from this expansion going towards further AI development. However, Apollo faces challenges such as high implementation costs, inconsistent data formats, and limited electronic medical records, which can slow AI adoption in the healthcare sector. Despite these challenges, healthcare providers believe that AI can improve efficiency and patient care, with investments expected to grow in the coming years.
Overall, Apollo’s increased investment in AI is a significant step towards improving healthcare operations and enhancing the patient experience. As the company looks to expand its bed capacity and AI capabilities, it will be interesting to see how it overcomes the challenges and maximizes the benefits of AI in the healthcare sector.
Contrary to allegations, Fortis Hospital Shalimar Bagh insists that they provided the patient with the best possible medical care, and denies any claims of medical negligence.
Fortis Hospital, Shalimar Bagh, has denied allegations of medical negligence made by the family of a patient who passed away on March 16, 2025. The patient, Manasvi Gupta, was admitted on March 10 with severe fever and seizures, indicating a complex neurological condition. The hospital stated that despite intensive care from a specialized medical team, including advanced respiratory and antimicrobial therapies, her medical complications worsened, and she passed away.
The hospital’s statement emphasizes that Manasvi received continuous care and monitoring from the multidisciplinary team, equipped with the latest medical technology, and that all treatment decisions were in line with the highest standards of medical practice. The hospital expresses its condolences to Manasvi’s family and reaffirms its commitment to providing the highest standards of medical care to all patients.
The case has been reported to the Shalimar Bagh police station, and a complaint has been lodged. The deceased’s body has been preserved at BJRM Hospital in Jahangirpuri for a post-mortem examination, which will be conducted after the constitution of a medical board by the NCT of Delhi. The investigation is ongoing, and allegations have been made that despite paying Rs 18 lakh, the patient did not receive adequate treatment. The hospital’s actions are under scrutiny, and the outcome of the post-mortem examination and investigation will determine the veracity of the allegations.
Novartis’ Lupin expands its US presence with FDA approval of Amifampridine, strengthening its portfolio of treatments for patients in the US.
The US Food and Drug Administration (USFDA) has granted tentative approval to Lupin Ltd’s Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder that affects communication between nerve and muscle. This approval allows Lupin to enter the market and offers a major market opportunity, as the reference drug Firdapse had global net sales of $306 million in 2024. The tablets will be manufactured at Lupin’s facility in Goa, boosting the company’s global manufacturing capabilities and commitment to providing affordable medications.
While the tentative approval meets all quality, safety, and efficacy requirements, final approval will depend on the expiration of or resolution of patent or exclusivity rights related to Firdapse. This approval aligns with Lupin’s focus on developing and expanding its presence in the US market. The successful launch of Amifampridine Tablets, 10 mg, will allow Lupin to capitalize on the large market for LEMS treatment, providing a major boost to its business and financials. With this approval, Lupin reinforces its position as a leading player in the global pharmaceutical industry, committed to delivering high-quality, affordable medications to patients worldwide.
Eli Lilly, Pfizer, and Teva Join Forces to Take On US Drug Price Negotiations
Eli Lilly & Co., Pfizer Inc., and other major pharmaceutical companies have joined forces to oppose the Medicare agency’s plan to negotiate drug prices. The companies, which also include Johnson & Johnson, Sanofi SA, Bausch Health Companies Inc., and the Biotechnology Innovation Organization, have filed a joint brief in support of Teva Pharmaceuticals Inc.’s suit against the Centers for Medicare & Medicaid Services (CMS) over the plan.
The Biden administration’s plan, which was introduced last year, allows the government to negotiate prices for certain high-cost Medicare Part B drugs. The opponents of the plan, including the pharmaceutical companies, argue that it violates federal laws and poses a threat to the industry’s innovative capabilities.
The main issue at stake is the process by which CMS will select the drugs to be included in the price-negotiation program. The companies are seeking to block the plan, which they believe is overly broad and could lead to the government picking and choosing which drugs to cover, potentially stifling innovation.
The proposed brief was filed on March 14 and argues that the government’s plan exceeds its authority under the Social Security Act and the Administrative Procedure Act. The brief also claims that the plan could lead to a decrease in investment in research and development, as well as a reduction in the number of treatments and cures available to patients.
The pharmaceutical companies’ opposition to the plan highlights the ongoing debate over the cost of healthcare in the United States and the role of the government in regulating the pharmaceutical industry. While the government’s plan may aim to reduce healthcare costs, the industry is concerned that it could have unintended consequences, such as stifling innovation and reducing access to life-saving treatments.
Overall, the showdown between the pharmaceutical companies and the government over the drug price negotiation plan is a significant development in the ongoing discussion about the future of healthcare in the United States. The outcome of the case is closely watched by stakeholders in the healthcare industry, who are waiting to see how the controversy will be resolved.
Introducing ‘Joint Preservation’ – A new initiative by Apollo Hospitals to promote healthy joints for a better quality of life
Apollo Hospitals has launched its “Joint Preservation Programme,” a comprehensive treatment plan designed to alleviate joint pain, arthritis, and inflammatory conditions, as well as ligament injuries. The programme is tailored to meet the unique needs of patients and is available at all Apollo Hospitals in India.
The programme aims to provide early intervention, personalized treatment, and rehabilitation to help individuals maintain their mobility and confidence. It focuses on the “3 T’s”: tailored advice, treatment (both medical and surgical), and therapies, including rehabilitation, nutrition, and alternative therapies.
Through this programme, patients will have access to a wide range of treatment options, including medical and surgical procedures, as well as alternative therapies like physical therapy, nutrition counseling, and complementary therapies. The programme is designed to help patients avoid invasive procedures and alleviate joint discomfort as quickly as possible.
The launch of the programme was marked by a press release from Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, who highlighted the importance of the programme in providing comprehensive care to patients. The programme is expected to benefit patients who have been previously advised to undergo treatment for their joint issues, as well as those seeking their first consultation for joint pain.
Several orthopedic specialists, including Dr. Brett Fritsch, Dr. KJ Reddy, and others, were present at the launch event, emphasizing the importance of prompt and effective treatment options for joint issues. With the launch of the Joint Preservation Programme, Apollo Hospitals aims to set a new standard in joint care, providing patients with a comprehensive and personalized approach to addressing their joint health concerns.
A 20-year-old’s life was tragically cut short, with her family accusing medical professionals of gross negligence in her untimely death.
A 20-year-old woman, Manasvi, died at Fortis Hospital in New Delhi due to alleged medical negligence by doctors, according to the Delhi Police. Manasvi was admitted to the hospital on March 10 with a fever and remained under treatment until her passing today. The cause of her death is currently unknown. The police received a call about a dispute between hospital staff and a patient’s family over alleged medical negligence. The police have registered a complaint at the Shalimar Bagh police station and have preserved the body at BJRM Hospital in Jahangirpuri for a post-mortem examination.
The victim’s family alleged that despite paying a hefty sum of Rs 18 lakh for treatment, Manasvi did not receive adequate care. The case has sparked outrage and concerns over medical negligence, leaving many to question the quality of healthcare in the country. The Delhi Police and the hospital administration are investigating the matter, with a medical board from the NCT of Delhi to be constituted to conduct a thorough investigation and determine the cause of her death. The incident highlights the need for greater transparency and accountability in the healthcare sector, as well as the urgent need for better training and education for healthcare professionals to ensure that such tragic incidents do not occur in the future.
Global business leaders from Qualcomm, Pfizer, and FedEx are set to visit China on March 23-24 for a meeting with President Xi Jinping.
A group of global CEOs from top companies, including Qualcomm, Pfizer, and FedEx, will be visiting China from March 23-24 to meet with Chinese President Xi Jinping. This meeting is significant as it marks the first time that global business leaders have been invited to visit China during the two-term limit of the country’s president.
The visit is seen as a move by China to strengthen its relations with the global business community and to promote economic cooperation. It is also a demonstration of China’s growing influence in the global economy, as well as its desire to establish itself as a major player on the world stage.
The CEOs of the top companies will have the opportunity to discuss with President Xi the current state of the economy, trade and investment opportunities, and other issues of mutual interest. The meeting is also expected to foster greater understanding and cooperation between Chinese and foreign companies.
China has been actively promoting its One Belt, One Road (OBOR) initiative, which aims to build a vast network of infrastructure, trade, and investment links between China and other parts of Asia, Europe, and Africa. The OBOR initiative is expected to have significant implications for global trade and investment, and the meeting with President Xi will likely focus on how global businesses can participate and benefit from this initiative.
The visit is also seen as a move by China to position itself as a key player in the global economy, particularly in the areas of technology, healthcare, and logistics. The CEOs of Qualcomm, Pfizer, and FedEx are among the most influential CEOs in the world, and their presence in Beijing will help to send a strong signal to global business leaders about China’s commitment to economic cooperation and mutual benefit.
Overall, the visit by the global CEOs to meet with President Xi is a significant event that is expected to have far-reaching implications for the global economy, trade, and investment. It is a demonstration of China’s growing influence and a testament to its ambition to become a leading player on the world stage.
Leading healthcare organization Apollo Hospitals boosts investment in AI technology, introducing innovative music therapy for cancer patients using artificial intelligence.
India’s Apollo Hospitals is increasing its investment in artificial intelligence (AI) to reduce the workload of its doctors and nurses by automating routine tasks such as medical documentation. According to Joint Managing Director Sangita Reddy, the hospital plans to free up two to three hours daily for doctors and nurses through AI interventions. Apollo is using AI to analyze patient electronic medical records, suggesting diagnoses, tests, and treatments, and transcribing doctor’s observations, among other tasks.
Apollo Hospitals, with over 10,000 beds, is one of the largest hospital networks in the country. The hospital is also expanding its bed capacity by one-third over the next four years, with a portion of the revenue dedicated to AI adoption. The hospital hopes AI will help manage workloads and improve efficiency as nurse attrition is expected to rise from 25% to 30% by 2025.
Other Indian hospitals, such as Fortis Healthcare, Tata Memorial, Manipal Hospitals, Narayna Health, Max Healthcare, and Aster DM Healthcare, have also invested in AI-powered tools. However, challenges such as high technology costs, diverse data sources, and limited electronic medical records remain barriers to accelerating AI adoption, says Deloitte India partner Joydeep Ghosh.
In another AI-related development, Apollo Proton Cancer Centre (APCC) has launched Asia’s first AI-based music therapy for cancer patients, in collaboration with DigiNxtHlt. The therapy uses AI to create a personalized soundscape for patients undergoing chemotherapy. The music therapy is designed to provide a soothing environment for cancer patients, and has been approved by the Apollo Ethics Committee and the Clinical Trials Registry.
Zydus Lifesciences’ Gujarat unit gains US FDA clearance following successful inspection
Zydus Lifesciences Ltd has successfully concluded a US Food and Drug Administration (USFDA) surveillance inspection at its API Unit 1 in Ankleshwar, Gujarat. The inspection, which took place from March 10 to 14, 2025, ended with “NIL observations,” indicating that the company demonstrated full compliance with quality and manufacturing practices.
The company’s financial performance has also been strong, with a 17% year-on-year revenue growth for the third quarter (Q3FY25) standing at ₹5,269 crore. The company’s net profit for the quarter was ₹1,023 crore, a 30% increase from ₹789 crore reported in the same quarter last year. A significant portion of this profit was driven by a forex gain of ₹183 crore, compared to a mere ₹21 crore in the previous year.
The company’s US formulation sales have continued to be a major driver, contributing to close to 47% of the top line. At $285 million, US formulation sales exceeded expectations, with a 29% year-over-year increase, beating analyst expectations of $270 million. This strong performance in the US market has been a significant contributor to Zydus Lifesciences’ overall growth.
Overall, the company’s successful USFDA inspection and strong financial performance suggest that Zydus Lifesciences is well-positioned for future growth and success. The company’s commitment to quality and manufacturing practices, as well as its strong performance in the US market, make it an attractive option for investors and customers alike.
After a successful treatment, ARR was cleared to leave the hospital.
Renowned music composer AR Rahman was discharged from Chennai’s Apollo Hospital after receiving treatment for health issues. According to a statement released by the hospital management, Rahman visited the hospital on March 16 with dehydration symptoms and underwent a routine check-up, following which he was discharged. This announcement put to rest rumors that had been circulating throughout the morning, indicating that the Oscar-winning musician had been admitted to the hospital due to chest discomfort after returning from London, where he attended an event.
Actually, Rahman had recently returned to Chennai and experienced neck and stomach pain, which he initially attributed to acidity and gastric issues. He self-medicated with antacids and anti-gas syrup at home, but when the discomfort persisted, he was taken to the hospital.
Rahman’s sister, Fathima, confirmed that her brother was hospitalized due to dehydration caused by his constant travel and lack of rest. He received drips and is now fine. Additionally, his son Ameen posted on his Instagram account that his father is doing well. The health scare appears to be attributed to exhaustion and dehydration, not any serious underlying condition. With his release from the hospital, AR Rahman is expected to resume his musical endeavors and continue to delight his fans worldwide with his melodious soundtracks.
Alkem Labs completes inspection process at Taloja Center
The article reports that Alkem Labs, a leading generic pharmaceutical company, has concluded an inspection at its Taloja Center facility. The inspection was conducted by the United States Food and Drug Administration (USFDA). The purpose of the inspection was to verify and assess the compliance of Alkem Labs’ manufacturing facilities, processes, and testing procedures with the current Good Manufacturing Practices (cGMPs) guidelines.
The inspection, which took place over a period of several days, aimed to ensure that Alkem Labs’ Taloja Center facility is adhering to the highest standards of quality, safety, and efficacy in the production and testing of pharmaceutical products. The inspectors assessed various aspects of the company’s operations, including the manufacturing, processing, and testing of its products, as well as the company’s record-keeping and documentation practices.
The inspection is a significant milestone for Alkem Labs, as it demonstrates the company’s commitment to ensuring the quality and safety of its products, as well as its compliance with international regulatory standards. Alkem Labs has built a strong reputation for its high-quality products and robust manufacturing processes, and this inspection is a further testament to its dedication to quality and customer satisfaction.
The outcome of the inspection is still pending, but Alkem Labs has reported that it has “full co-operation and support” from the USFDA during the inspection process. This suggests that the company is committed to working closely with the regulatory authorities to ensure its compliance and to address any issues that may arise.
In conclusion, the inspection by the USFDA at Alkem Labs’ Taloja Center facility is an important step towards ensuring the quality and safety of the company’s products. As a leading generic pharmaceutical company, Alkem Labs has a significant responsibility to its customers, patients, and regulatory authorities to maintain the highest standards of quality and compliance. This inspection is a crucial step in upholding that responsibility.
CDSCO’s panel recommends revising the phase III clinical trial protocol for Zydus Healthcare’s co-formulated Empagliflozin and Metoprolol Succinate
The Central Drug Standard Control Organization (CDSCO) has suggested revising the phase III clinical trial protocol for Zydus Healthcare’s Empagliflozin plus Metoprolol Succinate fixed-dose combination (FDC). The CDSCO’s suggestion aims to enhance the design and methodology of the trial, ensuring that it can provide more robust and reliable data for the approval of this new drug combination.
The CDSCO’s panel, which is responsible for overseeing clinical trials in India, has requested revisions to the protocol based on various factors, including the study’s duration, patient population, and endpoints. Specifically, the panel wants to see a longer trial duration to assess the long-term effects of the FDC on patients with type 2 diabetes.
The FDC, a fixed-dose combination of Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and Metoprolol Succinate, a beta-blocker, is being developed for the treatment of type 2 diabetes. The combination aims to improve glycemic control, reduce blood pressure, and lower the risk of cardiovascular disease.
Despite the CDSCO’s suggestions, the trial has already completed its phase II clinical trial, and Zydus Healthcare is now working to address the panel’s concerns and revise the protocol for phase III. The revised protocol will ensure that the study is more robust, well-designed, and can provide high-quality data to support the approval and registration of the FDC in India.
The revised protocol will likely include a longer study duration, increased patient numbers, and a more comprehensive set of endpoints to assess the efficacy and safety of the FDC. The trial will also need to demonstrate the superiority of the FDC over standard of care or other treatment options.
The revised protocol will be critical in ensuring that the FDC meets the necessary regulatory requirements, including those set by the Indian CDSCO. The approval of the FDC will depend on the successful completion of the revised phase III trial, which is expected to take around 2-3 years to complete.
Dr. Reddy’s divests 14 non-core assets to Senores Pharma, securing funding for its expansion into the US market.
Dr. Reddy’s, an Indian pharmaceutical company, has sold a portfolio of 14 Abbreviated New Drug Applications (ANDAs) to Ahmedabad-based Senores Pharmaceuticals. The acquired portfolio consists of 13 already approved ANDAs by the US Food and Drug Administration (FDA) and one pending approval. The market value of these ANDAs in the US is estimated to be between $421 million and $1.13 billion. Senores plans to fund the acquisition through proceeds from its upcoming initial public offering (IPO).
The acquired portfolio includes controlled substances and general category drugs that cater to demand across government, retail, and specialty clinics. Senores also sees strong growth potential in other regulated and semi-regulated markets worldwide. Dr. Reddy’s considers the products to be generic non-strategic assets.
The acquisition is a significant move for Senores, as it aims to expand its presence in the global generics market. The company plans to leverage the acquired portfolio to tap into new markets and further its growth trajectory.
It’s worth noting that Dr. Reddy’s has been streamlining its operations and focusing on its core products, which may have led to the divestment of this portfolio. The company has a history of acquiring and selling off non-core assets to focus on key areas of growth.
In related news, Dr. Reddy’s has been involved in several other transactions, including the settlement of a dispute with Impax over the generic version of Rytary. The company has also launched a generic version of Stromectol in partnership with Senores Pharmaceuticals. Overall, the sale of the ANDA portfolio is a significant move for Dr. Reddy’s, and it will be interesting to see how it impacts the company’s future growth and operations.
Apollo Hospital Marks World Sleep Day with a Sleep Health Initiative
In an innovative effort to raise awareness on the importance of sleep health, Apollo Specialty Hospital, Vanagaram organized India’s first sleep chain at the Vanagaram junction to commemorate World Sleep Day 2025. The event aimed to highlight the significance of sleep, with over 60% of Indians suffering from poor sleep quality, and its link to various health issues like heart disease, diabetes, and mental health disorders. The sleep chain, featuring doctors and nurses holding pillows with messages on the importance of sleep, is a powerful reminder that sleep is a biological necessity, not a luxury.
The initiative emphasizes the need for small but crucial lifestyle changes, such as consistent sleep schedules, reduced screen time, and seeking medical help, to address sleep disorders. Dr. Karthik Madesh, HOD and Clinic Head of the Institute of Sleep Health at Apollo Speciality Hospitals-Vanagaram, stressed that good sleep is critical to good health, citing its equal importance along with diet and exercise.
Dr. Prabhash Prabhakaran, HOD and Senior Consultant, Neurology, added that sleep is often underestimated as a fundamental pillar of health, and initiatives like the sleep chain play a vital role in highlighting its importance. He praised Apollo Specialty Hospital for its commitment to promoting sleep wellness and leading efforts to address sleep-related challenges.
The event was attended by experts, including Dr. Mohanakrishnan, Consultant, Pulmonology, and Dr. Rahul Raghav Menon, CEO and DMS, Apollo Speciality Hospitals, Vanagaram. Apollo Specialty Hospital is also home to the Institute of Sleep Health, a center dedicated to diagnosing and treating sleep disorders, including sleep apnea, insomnia, and narcolepsy. The hospital’s team of specialists, using advanced sleep studies and diagnostic tools, provides accurate assessments and tailored treatment plans to help patients achieve restorative sleep, leading to improved overall well-being and quality of life.
India now has access to a new treatment option for type 2 diabetes management as Glenmark Pharmaceuticals launches Empagliflozin, a medication designed to effectively control the disease.
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. The company has introduced three treatment options: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with type 2 diabetes (T2DM) and reduce cardiovascular outcomes in T2DM patients with cardiovascular risks.
Empagliflozin has been shown to be effective in reducing major cardiovascular events by 14% and has also been found to be effective in reducing weight and blood sugar levels in patients with T2DM. The medication has also been shown to be safe and well-tolerated in clinical trials.
Glenmark’s Glempa range is designed to cater to diverse patient needs, offering a standalone SGLT2 inhibitor, a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor, and a combination therapy combining SGLT2 inhibition with metformin. The company aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India.
Commenting on the launch, Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd, said: “Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”
Aurobindo Pharma Terminates Vaccine License Agreement with Hilleman Labs
Aurobindo Pharma, a pharmaceutical company, has terminated its licensing agreement with Hilleman Laboratories Singapore Pte Ltd for the development, manufacturing, and commercialization of a pediatric pentavalent vaccine candidate. The agreement was signed in September 2023 and was set to expire in 2025. As Auro Vaccines, the subsidiary responsible for the vaccine development, is not a material part of the company, Aurobindo Pharma expects the termination to have no significant impact on its financials or subsidiaries.
The agreement required Auro Vaccines to make milestone payments to Hilleman Laboratories upon achieving specific development and clinical study outcomes, as well as pay royalties to the Singapore-based company once the vaccine candidate was commercialized. Despite the termination, Aurobindo Pharma is not expected to experience any significant impact, and the company will make any necessary disclosures if the situation changes in the future.
The termination is viewed as a “non-material event” by Aurobindo Pharma, which suggests that the company does not expect to incur any substantial financial losses or liabilities as a result. This decision may indicate that the company is re-evaluating its priorities and focusing on more promising opportunities. As the deal was still in its early stages, the termination may not have significant implications for the pharmaceutical industry or the development of pediatric vaccines.
Zydus Lifesciences’ Ankleshwar unit secures successful US FDA inspection, adhering to stringent quality standards.
Zydus Lifesciences, a leading pharmaceutical company, has successfully completed a USA Food and Drug Administration (USFDA) inspection at its Ankleshwar facility. This achievement demonstrates the company’s commitment to maintaining the highest standards of quality, safety, and regulatory compliance.
The Ankleshwar facility, located in the Indian state of Gujarat, is one of the company’s key manufacturing units, producing a range of pharmaceutical products, including oral solid dosage forms, oral liquids, and pharmaceutical intermediates. The facility was inspected by a USFDA team from June 20 to July 1, 2022. The inspection was conducted as part of the USFDA’s routine surveillance program, which aims to ensure that pharmaceutical companies manufacturing products for the US market meet the agency’s Good Manufacturing Practices (GMPs).
The successful inspection was a culmination of Zydus Lifesciences’ rigorous efforts to ensure compliance with USFDA regulations. The company’s quality control measures, robust processes, and rigorous testing procedures were found to be satisfactory by the USFDA inspectors. The facility’s systems and procedures were also found to be compliant with the agency’s GMP guidelines.
The successful inspection paves the way for Zydus Lifesciences to continue exporting products to the US market, including critical and essential medicines, generics, and over-the-counter products. The company’s ability to pass the USFDA inspection is a significant achievement, demonstrating its commitment to quality and regulatory compliance.
In a statement, Zydus Lifesciences’ spokesperson said, “We are thrilled to have successfully passed the USFDA inspection at our Ankleshwar facility. This achievement is a testament to our team’s hard work and commitment to maintaining the highest standards of quality, safety, and regulatory compliance. We are proud to be a trusted partner in the global pharmaceutical industry, providing high-quality products to patients worldwide.”
This development is significant not only for Zydus Lifesciences but also for the Indian pharmaceutical industry as a whole. It highlights the country’s ability to manufacture high-quality products that meet global standards, thereby strengthening its position in the global pharmaceutical market.
In conclusion, Zydus Lifesciences’ successful USFDA inspection at its Ankleshwar facility is a significant achievement, showcasing the company’s commitment to quality, safety, and regulatory compliance. This achievement is a testament to the company’s rigorous processes and procedures, demonstrating its ability to meet global standards and ensuring access to high-quality pharmaceutical products for patients worldwide.
Here is one revised version of the line:Sun Pharma Fortifies East Coast Ties with New Jersey Office
The New Jersey Economic Development Authority (NJEDA) has approved tax credits for Sun Pharmaceutical Industries Inc. (Sun Pharma) to open a new US headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. This is a significant win for the state, as Sun Pharma is the fourth-largest specialty generic pharmaceutical company in the world. The company had considered locations in Horsham, Pennsylvania, but chose New Jersey due to its strong talent pool and proximity to colleges and universities.
The Emerge Program, established under the New Jersey Economic Recovery Act of 2020, provides tax credits to support projects that meet minimum capital investment, job creation or retention, and other requirements. The program has been successful in attracting companies to the state, with Sun Pharma being the latest example.
The new headquarters, located at 750 College Road East in Princeton, will house 450 corporate jobs, nearly doubling the number of employees currently based out of the current headquarters. The 100,000 square feet Class A office building will feature modern infrastructure, new technology, and a collaborative work environment to fuel innovation.
Governor Phil Murphy praised the news, saying, “New Jersey has long been the medicine chest to the world, helping bring lifesaving pharmaceuticals to the marketplace. Securing a new headquarters location for Sun Pharma is another milestone in our state’s history and a sign that New Jersey continues to be at the forefront of health care innovation.”
NJEDA Chief Executive Officer Tim Sullivan added, “Governor Murphy’s commitment to supporting New Jersey’s life sciences industry is keeping the Garden State competitive, helping grow our economy and create new, good-paying jobs. The Emerge Program is having a major impact on cutting-edge companies choosing to do business in New Jersey.”
Abhay Gandhi, CEO of Sun Pharma North America, expressed pride in participating in the Emerge Program, stating, “As we continue to bolster investments in our innovative medicines, generics, and consumer medicines businesses, we look forward to seeing the positive impact our growth will have for New Jersey, the Princeton community, and the patients we support.”
Zydus’ once-daily candidacy Illexcor emfaces a new opportunity to combat Sickle Cell Disease.
Zydus, an Indian pharmaceutical company, has made a significant move in the competitive field of sickle cell disease treatment by acquiring a stake in US-based Illexa, a company developing a once-daily oral treatment for the disease. This acquisition provides Zydus with a foothold in the market, allowing it to piggyback on the promising preclinical results of Illexa’s therapy.
Sickle cell disease is a debilitating genetic disorder that affects millions of people worldwide, with limited treatment options. Global pharmaceutical majors like Novartis, Pfizer, and Novo Nordisk have all attempted to develop treatments for the disease, but with mixed results. Novartis’ Crizalbinemab, for example, showed promise in clinical trials but was ultimately failed to meet its primary endpoint. Pfizer’s P.vo lead candidate did not meet its primary endpoint in a late-stage trial, while Novo Nordisk’s candidate Liso-cel did not demonstrate consistent results across multiple trials.
Illexa’s once-daily oral treatment, on the other hand, has shown promising preclinical results, which could potentially change the treatment landscape for sickle cell disease. Zydus’ acquisition of a stake in Illexa provides the company with a strategic entry point into this high-demand market, allowing it to leverage Illexa’s research and development expertise to potentially bring a new treatment option to market.
The acquisition also reflects Zydus’ growing presence in the global pharmaceutical industry. With a presence in over 40 countries, Zydus has been expanding its presence in the global market through strategic acquisitions and partnerships. The Illexa deal is the latest in a series of moves by the company to diversify its portfolio and increase its global presence.
In summary, Zydus’ acquisition of Illexa provides the company with a foothold in the lucrative sickle cell disease treatment market, backed by promising preclinical results. This strategic move reflects Zydus’ commitment to expanding its presence in the global pharmaceutical industry, and its ability to identify and capitalize on opportunities in high-demand therapeutic areas.
A study by Apollo Bangalore reveals that men are three times more likely to receive kidney transplants, highlighting a significant trend in the healthcare sector.
According to recent data from Apollo Bangalore, men are three times more likely to receive kidney transplants compared to women. The Apollo Healthcare data analysis reveals significant disparities in kidney transplant rates between males and females.
The study found that 43.2% of all kidney transplants were performed on male recipients, while 14.5% were for female recipients. This disparity is attributed to various factors, including the higher incidence of chronic kidney disease (CKD) and faster progression of kidney damage in men.
Researchers also discovered that men are more likely to suffer from hypertension, a significant risk factor for CKD. Moreover, men are more likely to experience kidney damage caused by factors such as diabetes, obstructive sleep apnea, and certain medications.
The Apollo Bangalore data analysis also showed that the frequency of kidney transplants in both men and women varied significantly with age. The majority of kidney transplants (45.1%) were performed on individuals between the ages of 45 and 64 years. In contrast, only 24.5% of transplants were performed on individuals under the age of 45.
In terms of the hashtags, it seems like the profile of the recipient of kidney transplants is changing dramatically: #Apollobangalore #Kidney transplantation #Transplantrates #TRENDS
Glenmark Pharma introduces Empagriflozin and its complementary formulations to the Indian market
Glenmark Pharmaceuticals Ltd. has launched its new product range, Glempa, in India. The range consists of Empagliflozin, a widely recognized SGLT2 inhibitor, in three forms: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with type 2 diabetes (T2DM) and reduce cardiovascular outcomes in T2DM patients with cardiovascular risk.
Empagliflozin is a well-established treatment for heart failure, T2DM, and T2DM with cardiovascular disease, offering multiple benefits such as cardiovascular and renal safety. A clinical trial demonstrated a 14% reduction in major cardiovascular events, making Empagliflozin a significant advancement in T2DM patients with high CV risks.
Studies have shown that Empagliflozin and its combinations are effective in reducing blood sugar levels, weight loss, and fasting blood sugar. A study found that a combination of Empagliflozin and Metformin helped patients lower their blood sugar levels, lose weight, and reduce fasting blood sugar. Another study showed that Empagliflozin with Linagliptin helped patients lower their HbA1c, lose weight, and reduce fasting blood sugar, proving more effective than either medicine alone.
Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., commented on the launch, stating that Glenmark is committed to providing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution for healthcare professionals and patients to manage T2DM with established CVD more effectively.
The Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. The Glempa range is expected to empower healthcare professionals and patients to manage T2DM with CVD more effectively, providing a range of treatment options for improved patient care.
Alkem Laboratories’ Bioequivalence Center achieves clean record with US FDA inspection, passing with zero observations.
Alkem Laboratories, a leading pharmaceutical company in India, has announced that its Bioequivalence Center has successfully cleared a inspection by the United States Food and Drug Administration (USFDA) without any observations. This achievement is a significant milestone for the company, demonstrating its commitment to maintaining the highest standards of quality and regulatory compliance.
The USFDA inspection was conducted to ensure that Alkem’s Bioequivalence Center, which is responsible for testing and evaluating the bioequivalence of pharmaceutical products, meets the regulatory requirements of the FDA. The inspection covered various aspects, including the center’s infrastructure, equipment, processes, and personnel.
Alkem Laboratories’ Bioequivalence Center is equipped with state-of-the-art facilities and cutting-edge technology, enabling it to conduct complex bioequivalence studies for a wide range of pharmaceutical products. The center is staffed by a team of experienced professionals who are well-versed in the latest regulatory requirements and industry best practices.
The successful inspection by the USFDA is a testament to the center’s ability to maintain high-quality standards and adhere to regulatory guidelines. This achievement is a significant boost to the company’s reputation and allows it to offer its services to clients in the pharmaceutical industry with confidence.
Alkem Laboratories is committed to sustaining its reputation for quality and compliance, and this achievement is a reflection of its dedication to meeting the stringent requirements of the USFDA. The company’s Bioequivalence Center has been recognized for its expertise and capabilities, and this inspection success is a major milestone in its journey to become a leading provider of bioequivalence testing services in the global pharmaceutical industry.
The news is a significant development for Alkem Laboratories, which has been working to expand its presence in the global pharmaceutical industry. The company has been making concerted efforts to invest in its research and development capabilities, as well as its manufacturing infrastructure, to meet the growing demand for high-quality pharmaceutical products.
In conclusion, Alkem Laboratories’ Bioequivalence Center’s successful inspection by the USFDA without any observations is a significant achievement, demonstrating the company’s commitment to quality and regulatory compliance. This achievement is likely to enhance the company’s reputation and credibility in the pharmaceutical industry, and it is expected to open up new opportunities for the company to expand its offerings and reach new markets.
Unleashing New Frontiers: Aurobindo Pharma’s Diversification Drive Paves the Way for Future Growth
Aurobindo Pharma, a leading drugmaker, is focusing on sustaining profitability and turnover in the face of rising global uncertainties. According to Chief Financial Officer Santhanam Subramanian, the company’s strategy is centered on scale and diversity, with a goal of expanding into new verticals such as injectables, peptides, and biosimilars. This diversification will help minimize the impact of a potential tariff hike in the US and maintain margins.
Aurobindo has been steadily expanding its presence in the market, starting with a small API business in India, followed by the US, Europe, and other parts of the world. The company is also entering the Chinese market, which is expected to contribute to its growth in 2-3 years.
The company’s diversified portfolio allows it to overcome the risks associated with price erosion, as 10% of its top products account for 20% of its US turnover. Aurobindo does not differentiate between “bread and butter” and high-growth segments, nurturing all verticals independently to ensure consistent contribution to overall growth.
In terms of cash flow generation, Aurobindo is planning to expand its existing projects and open new plants, including a US-based plant and a biosimilar facility. The company’s strong cash flow generation allows it to strategically allocate capital towards new verticals and expansion projects.
Aurobindo’s net debt stands at $84 million, with projections to generate $200-300 million annually. The company has a robust product pipeline, with over 850 ANDAs filed and 150-200 awaiting approval. The new verticals of biosimilars, Eutect, Terany, and Biologics are expected to drive growth in the coming years.
Overall, Aurobindo Pharma is confident in its ability to sustain healthy margins and drive growth through its focus on scale and diversity, robust cash flow generation, and strong product pipeline.
India sees a significant decrease in the price of a commonly used diabetes medication following the introduction of generic alternatives.
The price of the diabetes drug empagliflozin, also known as Jardiance, has been significantly reduced by almost one-tenth in India. The drug, developed by German pharma giant Boehringer Ingelheim, is used to control blood sugar levels in patients with type 2 diabetes. The original price of the drug was around Rs 60 per tablet, but with the entry of its generic versions in the market, it is now available for as low as Rs 5.5 per tablet.
Mankind, Alkem, and Glenmark Pharmaceuticals have launched generic versions of empagliflozin, with prices starting from Rs 5.49 per tablet for the 10 mg variant. These prices are nearly 80% lower than the original price of the innovator product. The generic versions of the drug come with additional features, such as anti-counterfeit security bands, patient education information, and QR codes that provide prescribing information and additional patient education.
The launch of these generic versions of empagliflozin is a significant step in making the drug more affordable for millions of Indians who are suffering from type 2 diabetes. India is known as the diabetes capital of the world, with over 10 crore people diagnosed with the disease, according to the Indian Council of Medical Research–India Diabetes (ICMR INDIAB) study in 2023. Reducing the cost of anti-diabetes medicines like empagliflozin is a crucial step in tackling the disease burden in the country.
Pfizer Records $1 Sale of ‘Surplus’ Land to Portage, Offloading Underutilized Property
The City of Portage, Michigan has acquired a new piece of land, thanks to a unique deal with Pfizer. The company, which previously owned the property on Lovers Lane, has offered to sell it to the city for just $1. The land, which is situated between Stryker Way and Ramona Avenue, is adjacent to properties already owned by the city, making it a prime opportunity for expansion and preservation. Additionally, the property is bordered by Portage Creek, which defines the eastern boundary, and the city already holds an easement along the western edge for the Portage Creek Bicentennial Park Trail.
The city’s acquisition of this land will allow for contiguous ownership along the western edge of Portage Creek, preserving valuable green space and enhancing the community’s stewardship efforts. The city is thrilled to have secured this unique opportunity, and officials praise Pfizer’s “generous offer” and “strong corporate responsibility.” The sale reflects a positive partnership between the city and the corporation, demonstrating that public-private collaborations can lead to mutually beneficial outcomes. With this acquisition, the city will be able to expand its environmental preservation efforts, protecting natural habitats and providing recreational spaces for residents to enjoy.
Apollogroup’s Healthcare Summit, ASPIRE 2025, Brings Together Experts to Strategize Innovative Solutions for Interstitial Lung Disease Treatment
The Apollo Symposium on Pulmonary Interventions and Respiratory Excellence (ASPIRE) 2025 was recently held in Hyderabad, Telangana. The event brought together pulmonologists, rheumatologists, and healthcare professionals to discuss recent advancements in the diagnosis and management of Interstitial Lung Disease (ILD), a condition that affects an estimated 4-8 lakh people in India.
The symposium focused on bronchoscopic techniques, high-resolution imaging, and biomarker-driven diagnostics that are improving ILD detection. Experts also examined new pharmacological treatments, including antifibrotic drugs and biologics, which are shaping ILD management in India.
The event featured participation from leading international and national medical professionals, including experts from the University of Washington Medical Center, University of Cincinnati, and Baylor College of Medicine, among others.
The Apollo Hospitals Pulmonology Department organized the event, led by Dr. Sowmya Parimi, Dr. Vijay Kumar Chennamsetty, and other committee members. The symposium covered topics such as AI-driven diagnostics, cryobiopsy for tissue acquisition, pulmonary rehabilitation, lung transplantation, and remote monitoring for ILD patients.
Apollo Hospitals’ CEO, Mr. V Tejesvi Rao, highlighted the importance of integrating cutting-edge technology in respiratory care, while Dr. Ravindra Babu, Director Medical Services, emphasized the need for a collaborative approach to diagnose and manage ILD. The event served as a crucial knowledge-sharing platform, fostering collaboration among specialists to advance data-driven ILD diagnosis and targeted therapeutic interventions.
ASPIRE 2025 marked an important step in improving ILD management across India, with Apollo Hospitals committed to pioneering evidence-based and technology-driven respiratory care. The event reflects the hospital’s dedication to providing the best available care to patients and contributing to the advancement of medical knowledge.
Torrent Pharmaceuticals’ (NSE:TORNTPHARM) appears to be well-equipped to navigate its debt obligations with confidence.
The article discusses Torrent Pharmaceuticals’ (NSE:TORNTPHARM) ability to manage its debt with ease. The company has a debt-to-EBITDA ratio of 1.1, which is manageable, and its interest coverage ratio is a significant 12.3, indicating that the company has a strong ability to pay its debts. The company’s debt level has been increasing due to the acquisition of HOS, but the benefits from the acquisition, such as increased profitability and revenue, have helped to alleviate the debt burden.
The article notes that Torrent Pharmaceuticals has a strong track record of generating positive cash flows, which has helped to reduce its debt over the years. The company has also been actively managing its Working Capital Adjudication (WCA) process, which has led to a reduction in its debt levels.
The article also provides a brief overview of Torrent Pharmaceuticals’ recent performance, including its revenue and profitability growth, as well as its dividend yield and shareholder return. The company has a strong track record of paying dividends, with a dividend yield of 1.1%, making it an attractive option for income-seeking investors.
In conclusion, the article suggests that Torrent Pharmaceuticals is well-positioned to manage its debt with ease, thanks to its strong cash flows, efficient use of working capital, and proven track record of generating positive returns for shareholders. Its decent interest coverage ratio and manageable debt-to-EBITDA ratio also indicate that the company is capable of servicing its debt comfortably.
However, it’s worth noting that the article is just a brief summary, and it would be a good idea to review the company’s latest financials and reports to get a more comprehensive understanding of its financial health and borrowing capacity.
Sikkim Governor Unveils Community Hall in Pakyong, Flags Off Sulabh Alkem Award 2024
The Sulabh Alkem Award 2024 ceremony was held at the Integrated Multipurpose Hall in Pakyong, Sikkim, where Governor Om Prakash Mathur attended as the chief guest. The event recognized the outstanding contributions of individuals and institutions to sanitation and hygiene under Project AagazPlus, an initiative aimed at promoting accessible and hygienic sanitation in schools, with a focus on girls’ education and empowerment. The project integrates hygiene improvement in schools through practices such as handwashing with soap, access to clean drinking water, and use of improved sanitation facilities.
Governor Mathur emphasized the importance of hygiene and sanitation, praising the Sulabh Sanitation Club and Alkem Foundation for their efforts in introducing Project AagazPlus to schools. He highlighted the need for initiatives that foster healthier lifestyles among students. The Governor also inaugurated the Integrated Multipurpose Community Hall, a CSR project by the Airports Authority of India.
The event featured testimonials from various stakeholders, including students and teachers, who shared their positive experiences with the project. The Sulabh Alkek Award 2024 recognized schools, teachers, and volunteers for their outstanding work in promoting WASH (water, sanitation, and hygiene) initiatives under Project AagazPlus. Some of the award winners included Government Secondary School, Dalapchand, and teachers Ruchi Thapa, Aquino Sharma, Karma Kunsang Tamang, and Santosh Chettri. The awards also recognized volunteers Ayesha Khatun, Ayogita Sharma, and Ayush Thapa.
Overall, the event aimed to promote better hygiene and sanitation practices in schools, and the importance of girls’ education and empowerment. The award ceremony also acknowledged the efforts of various stakeholders, including the Sulabh Sanitation Club, Alkem Foundation, and the Education Department, in promoting WASH initiatives in schools.
Novo Nordisk launches AjaDuo, a new fixed-dose combination of empagliflozin and linagliptin, at an affordable price.
Lupin, a leading pharmaceutical company, has announced the launch of AjaDuo, a fixed-dose combination (FDC) of empagliflozin and linagliptin, at an affordable price. The launch is a significant development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and cost-effective treatment option.
AjaDuo is a combination therapy that combines the benefits of two medications: empagliflozin, an SGLT-2 inhibitor, and linagliptin, a DPP-4 inhibitor. This combination has been shown to improve glycemic control and reduce blood sugar levels. The fixed-dose combination is expected to offer benefits such as improved patient adherence, reduced pill burden, and enhanced convenience.
Lupin’s AjaDuo is priced competitively, making it an attractive option for patients with type 2 diabetes who require combination therapy. The company’s efforts to launch affordable medications are aimed at increasing access to quality healthcare, particularly in developing countries like India where healthcare infrastructure is often limited.
The launch of AjaDuo is a strategic move by Lupin to expand its presence in the diabetes market, which is one of the fastest-growing therapeutic segments globally. The company’s portfolio already includes several popular diabetes drugs, and the launch of AjaDuo is expected to further strengthen its position in this space.
The availability of AjaDuo at an affordable price is expected to benefit millions of patients with type 2 diabetes, who may not have access to branded treatments or may be forced to compromise on their treatment due to cost constraints. The launch is a significant step towards increasing access to quality healthcare for patients, especially in emerging markets.
Overall, the launch of AjaDuo by Lupin is a positive development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and affordable treatment option. The company’s initiatives to make high-quality medications accessible at affordable prices are likely to benefit millions of patients across the country.
Managing Drug Awareness and Media Communications
The provided content appears to be a news article or a publication from DrugsControl.org, a website that seems to focus on drug-related news, information, and control services.
The content is a collection of various news articles and updates from 2025, with no specific title or heading. The article appears to be a compilation of several news stories, with each story summarizing an event or development related to drugs, drug control, and drug policy.
Some of the topics covered in the article include:
1. Drug-related news and updates from around the world, including reports of drug-related crime, seizures, and arrests.
2. Summaries of conferences, meetings, and events related to drug control and policy, including statements from government officials and international organizations.
3. Reports on drug-related research and studies, including findings on the effects of drugs on health, addiction, and social behaviors.
4. Updates on drug policy, including changes to laws and regulations, international agreements, and trends in drug control.
The article also includes links to other relevant news stories and resources, as well as a copyright notice and a statement indicating that the website was last updated on December 3, 2025.
Overall, the content appears to be a repository of information related to the control and regulation of drugs, with a focus on news, research, and policy developments. The article is likely intended for readers interested in drug control, public health, and law enforcement.
Indian pharma companies will introduce affordable generic versions of empagliflozin, a WedMD medicine used to treat type-2 diabetes.
Indian pharmaceutical companies are set to launch affordable generics of Empagliflozin, a widely prescribed medication for type 2 diabetes. Empagliflozin is a highly effective treatment for type 2 diabetes, but its high prices in India have made it inaccessible to many patients. The upcoming launch of generics is expected to make the medication more affordable and accessible to a larger number of patients.
Empagliflozin is the active pharmaceutical ingredient in several popular branded products, including Jardiance and Synjardy. It is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor that helps the kidneys to filter out excess sugar from the blood, reducing the risk of complications associated with type 2 diabetes. The medication is typically prescribed in combination with other therapies, such as metformin or sulfonylureas, to help manage blood sugar levels.
Indian generic pharmaceutical companies, including Dr. Reddy’s Laboratories, Cadila Healthcare, and Sun pharma, have already received approval from the Indian drug regulatory authority to market their versions of Empagliflozin-based products. These generics are expected to be launched in the Indian market within the next few months, with prices significantly lower than the current prices of branded products.
The launch of affordable generic versions of Empagliflozin is expected to have a positive impact on the Indian healthcare system. Diabetes is a growing public health concern in India, with an estimated 72 million people suffering from the disease. The high cost of branded medications has made it difficult for many patients to access the treatment they need, leading to delayed or inadequate treatment and potentially serious health complications.
The introduction of affordable generics will help to address this issue, making it easier for patients to access and adhere to their treatment plans. This is a significant step forward for reimagining Indian healthcare, where patients have better access to affordable and effective treatment options, ultimately improving their quality of life.
Apollo Hospitals Unveils ASPIRE 2025, A Comprehensive Plan to Combat Interstitial Lung Disease Through Strategic Interventions
The Apollo Hospitals group hosted the ASPIRE 2025 symposium, a conference focused on pulmonary interventions and respiratory excellence, in Hyderabad. The event aimed to address Interstitial Lung Disease (ILD), a condition that affects an estimated 4-8 lakh people in India, with rising prevalence due to increasing air pollution, occupational hazards, and delayed diagnosis.
The symposium brought together pulmonologists, rheumatologists, and healthcare professionals to discuss advancements in bronchoscopic techniques, high-resolution imaging, and biomarker-driven diagnostics for ILD detection. Experts also explored new pharmacological treatments, including antifibrotic drugs and biologics, which are shaping ILD management in India.
The event featured international and national medical professionals, including Dr. Ganesh Raghu, Dr. Nishant Gupta, and Dr. Kalpalatha Guntupalli, among others. The Apollo Hospitals’ organizing committee, led by Dr. Sowmya Parimi and Dr. Vijay Kumar Chennamsetty, successfully conducted the conference, which covered AI-driven diagnostics, cryobiopsy for tissue acquisition, pulmonary rehabilitation, lung transplantation, and remote monitoring for ILD patients.
Apollo Hospitals’ CEO, Mr. V Tejesvi Rao, emphasized the organization’s commitment to integrating cutting-edge technology in respiratory care, stating that AI-driven imaging and biomarker-based diagnostics are transforming ILD detection, enabling earlier and more precise diagnoses. Dr. Ravindra Babu, Director Medical Services, Telangana Region, Apollo Hospitals, added that chronic respiratory diseases, including ILD, account for more than 12% of all deaths in India, and accurate diagnosis and tailored treatment plans are crucial.
ASPIRE 2025 served as a knowledge-sharing platform for specialists to advance data-driven ILD diagnosis and targeted therapeutic interventions. Apollo Hospitals’ commitment to pioneering evidence-based and technology-driven respiratory care marked an important step in improving ILD management across India. The hospital group’s goal is to bring cutting-edge technologies, equipment, and treatment protocols to ensure patients receive the best care available. With over 10,000 beds across 73 hospitals, 6,000 pharmacies, and 2,000 clinics and diagnostic centers, Apollo Hospitals is India’s largest integrated healthcare platform.
Fortis Escorts Amritsar organized an exclusive ECHO workshop at its annual cardiology summit, showcasing the latest advancements in the field.
The 2025 Cardiology Summit, hosted by Fortis Escorts, Amritsar, brought together leading cardiologists from the North Zone/North India to discuss the latest advancements in echocardiography, a crucial tool in the diagnosis and management of heart diseases. The two-day ECHO workshop, led by experts Dr. HarinderPal Singh, Dr. Arun Kumar Chopra, and Dr. Deepak Kapila, focused on topics such as arrhythmias, coronary artery disease, heart failure, and hypertension, which are major contributors to cardiovascular morbidity and mortality.
The workshop highlighted the significance of LV systolic function in evaluating heart efficiency, the role of echocardiography in structural interventions, and the assessment of aortic stenosis and valvular heart disease. The experts also emphasized the importance of echocardiography in pediatric cardiology, early diagnosis, and management of congenital heart conditions.
The summit aimed to bridge the gap between theoretical knowledge and real-world clinical practice, providing hands-on learning experiences for cardiologists. The directors of the cardiology department at Fortis Escorts, Amritsar, stressed the need for continuous learning, collaboration, and innovation to improve patient outcomes. Dr. HarinderPal Singh noted that the goal was to equip specialists with advanced imaging techniques to enhance early detection and patient outcomes. Dr. Arun Kumar Chopra highlighted the role of echocardiography in transforming cardiac care, while Dr. Deepak Kapila emphasized the importance of fostering an environment where experts can exchange ideas and refine their techniques to detect and manage complex cardiac conditions at an early stage.
The 2025 Cardiology Summit reinforced Fortis Escorts’ commitment to advancing cardiac care through education, innovation, and collaboration, empowering medical professionals with cutting-edge echocardiographic techniques to improve cardiovascular health outcomes across India.
Glenmark Therapeutics Inc. introduces Polyethylene Glycol 3350, a gentle, 17g/capful (OTC) powder for solution, now available in the USA.
Glenmark Therapeutics Inc., a US-based company, has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC), a product that is comparable to the active ingredient in MiraLAX Powder for Solution, 17 grams from Bayer HealthCare LLC. According to Nielsen data, the MiraLAX product achieved annual sales of approximately $555.7 million in the latest 52-week period ending February 22, 2025.
The new product marks Glenmark’s entry into the market, which is expected to cater to the growing demand for a new supplier in this category. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed excitement about the launch, stating that it reflects the company’s commitment to meeting market needs and providing high-quality over-the-counter solutions for its customers.
The launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful is expected to give Glenmark a foothold in the market, which has been dominated by MiraLAX. The company’s entry into this category is a significant development, and it will be interesting to see how the market responds to this new competitor. With its commitment to providing high-quality products, Glenmark is likely to make a positive impact in the market. As the company continues to expand its portfolio, it will be worth monitoring to see how it fares in the competitive OTC market.
This popular diabetes medication is set to get a significant price cut, dropping from Rs 60 to just Rs 9 per unit.
The cost of Empagliflozin, a crucial drug for managing diabetes and its associated conditions, is set to drop significantly in India. The price of the medicine, which was previously around Rs 60 per tablet, will be reduced to just Rs 9 per tablet, making it more accessible to millions of diabetes patients in the country. This development comes after the patent for the drug, which was previously held by German pharmaceutical company Boehringer Ingelheim, expired on March 11.
As a result, Indian pharmaceutical companies such as Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin will be able to introduce their own versions of the drug, offering patients cheaper alternatives. Mankind Pharma, for example, plans to offer the drug at a price 90% lower than the innovator company, making it more affordable for patients.
Empagliflozin plays a crucial role in preventing heart failure and delaying kidney failure, making it a vital medication for those with diabetes. However, its high cost has previously made it difficult for many to access. The introduction of more affordable options from Indian companies is expected to bring significant benefits to millions of patients.
The reduced price of Empagliflozin is poised to provide much-needed financial relief to diabetes patients, who often face the burden of out-of-pocket medication expenses. In India, over 10.1 crore people are living with diabetes, and limited insurance coverage often leaves patients to shoulder medication costs independently. The availability of more affordable options is expected to make a significant difference in the lives of these patients.
The economic burden of diabetes in India is substantial, and the reduced price of Empagliflozin is a welcome development for diabetic patients across the country. With the introduction of more affordable alternatives, millions of patients will have access to a vital medication, allowing them to better manage their condition and improve their overall health.
Brooklyn Brownstone Where Pfizer Co-Founder Breathes Life into His Legacy Sells for $10.35 Million, Reflecting Its Value as a Rare Gem in the Market
The Brooklyn Brownstone is a stunning 4,200 square-foot property in Brooklyn, New York that was built by the co-founder of Pfizer, Charles F. Palm. The mansion is currently on the market for a staggering $10.35 million.
The property, which was constructed in the late 19th century, features a blend of Victorian and Italianate architectural styles. The exterior is adorned with intricate details, including ornate brickwork, ornamental tin cornices, and carved wooden shutters. The interior boasts high ceilings, hardwood floors, and stunning chandeliers, creating a luxurious atmosphere.
Upon entering the property, one is immediately struck by the grand foyer, which features a sweeping staircase and a curved balcony overlooking the gracious reception area. The property’s five floors are filled with an impressive array of rooms, including six bedrooms, six bathrooms, and six working fireplaces. The estate also features a generous playroom, a library, and a formal dining room perfect for entertaining.
The property’s architecture is not only aesthetically pleasing but also exudes quality finishes and materials. The property features high-end amenities such as a smart home system, a security system, and a private elevator.
One of the crowning jewels of the property is its outdoor spaces. The rear garden is a tranquil retreat, complete with a private fence, a pool, and a patio area perfect for al fresco dining. The property also features a roof deck offering breathtaking views of the Manhattan skyline.
The location of the property is also a major draw. The Brooklyn Brownstone is situated in one of Brooklyn’s most desirable neighborhoods, surrounded by top-rated schools, parks, and restaurants. The property is also just a short distance from Manhattan, making it an ideal choice for those who want to enjoy the best of both worlds.
With its stunning architecture, luxurious finishes, and desirable location, the Brooklyn Brownstone is an unparalleled opportunity for those seeking a one-of-a-kind home. At $10.35 million, it’s a price tag that’s only for the most discerning buyer.
A two-day surgical conference for otorhinolaryngology (ENT) specialists at Fortis Hospital, Mohali.
The ENT Surgical Conclave 2025, a two-day conference, was held at Fortis Hospital, Mohali, to highlight the latest advancements in robotic-aided surgery for ear, nose, and throat (ENT) disorders. The conference was organized by the Department of ENT, Head, and Neck Surgery, in collaboration with the All-India Rhinology Society and the Punjab Medical Council. The event brought together over 200 delegates, including junior and senior residents from various medical colleges across the country, for a knowledge-sharing experience. The conference featured six live surgeries, panel discussions, poster presentations, and a quiz, and was attended by renowned otolaryngologists.
The chief guest, Aman Arora, President of the Aam Aadmi Party (Punjab), praised the medical fraternity for their dedication to advancing healthcare in the state. He emphasized the importance of innovation and knowledge-sharing in the healthcare system, noting that doctors are the backbone of the healthcare infrastructure. Dr. Ashok Gupta, Director of the ENT department, Fortis Hospital, Mohali, highlighted the conference’s focus on the latest advancements in otorhinolaryngology and the use of robot-aided surgery in the treatment of ENT disorders and head and neck cancer surgeries. The event aimed to enhance medical expertise and benefit citizens, aligning with the vision of the CM Bhagwant Singh Mann-led government. The successful conclave demonstrated the hospital’s commitment to promoting medical excellence and advancing healthcare in the state.
Mahavir International receives prestigious ‘Glenmark Nutrition Award 2025’ in Nagpur
Mahavir International’s “Project Vatsalya – Pregnancy to Infancy” has been recognized for its outstanding efforts in eradicating malnutrition among women and children. The initiative received the prestigious Glenmark Nutrition Award 2025, which comes with a grant of Rs 2 lakh to support the expansion of the project. The award was established by the Glenmark Foundation and IDBRO to recognize organizations working towards eliminating malnutrition among pregnant and lactating women and children. Out of 403 nominations from across the country, Mahavir International’s Project Vatsalya was judged to be the best in the voluntary open category.
Dr. Veera Rashmi Saraswat, International Director of Women & Child Welfare – Vatsalya, presented the project to the grand jury in Mumbai, highlighting its efforts to combat malnutrition. The initiative is part of the National Nutrition Mission (Poshan Abhiyaan) and has been working tirelessly to address the issue of malnutrition among women and children. The award is a testament to the project’s dedication and commitment to improving the lives of these vulnerable groups.
The grant of Rs 2 lakh will enable Mahavir International to further extend the reach and impact of Project Vatsalya, making it a significant step towards a malnutrition-free society. The recognition is a proud moment for the organization, and Dr. Saraswat emphasized that the team will continue to work towards addressing this critical issue, which affects not only individual health but also the overall development of the country. With this award, Mahavir International’s Project Vatsalya has set a shining example for organizations working towards a similar cause, and its success will undoubtedly inspire others to follow in its footsteps.